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Research activity 
 
My research activity was focused on two subjects. 
 
The first phase of my research activity was carried out in the laboratory of Prof. 
Renata Piccoli of the University of Naples “Federico II”, where I worked on a research 
project aimed at the construction of a new anticancer immunoagent, the compact 
antibody Erb-hcAb. Computational analyses for the construction of a homology 
model of the compact antibody  binding domain were performed in the laboratory of 
Prof. Anna Tramontano of the University of Rome “La Sapienza”.  
 
The second phase of my research activity was carried out in the Immunopathology 
laboratory of the “Umberto I” hospital, Nocera Inf. (SA), under the supervision of Dr. 
Paola Sabatini. The objective of this part of my research activity was the evaluation 
of the efficacy of a new diagnostic test for rheumatoid arthritis, based on 
cytofluorimetry.  
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 ABSTRACT 
 
A NEW TOOL FOR ANTICANCER THERAPY: THE ANTI-ErbB2 COMPACT 
ANTIBODY 
Immunotherapy represents a valuable alternative strategy to fight cancer, mainly 
based on antibodies specifically directed to selected cancer cells. A good candidate 
as a tumour-associated antigen (TAA), and an attractive target for immunotherapy is 
ErbB2 receptor, over-expressed in breast, ovary and lung carcinomas. Recently, a 
novel human scFv anti-ErbB2, named Erbicin, was isolated from a large phage-
display library. It was found to exhibit a selective anti-proliferative effect on cancer 
cells over-expressing the ErbB2 receptor. However, the small size of the scFv, as 
well as the monovalent nature, could limit its use as a therapeutic agent for cancer. 
During my research work, I prepared a new human immunoagent, named “compact 
antibody”, by protein engineered. It was generated by fusing the human anti-ErbB2 
scFv (Erbicin) with a human IgG1 Fc domain. This chimeric molecule, named Erb-
hcAb, has a molecular size of about 100 kDa, higher than that of a scFv molecule, 
but smaller than that of a whole antibody. It presents two antigen-binding sites and it 
is expected to have a potential prolonged clearance from the bloodstream and to 
elicit the Fc-mediated effector functions.  
This new immunoagent was found to selectively bind to ErbB2-positive cells, and to 
strongly inhibit their proliferation. Hence, Erb-hcAb fully satisfies the conditions 
required for a successful anticancer agent: it is a fully human immunoagent, with 
expected low immunogenicity; it binds selectively and with high affinity to ErbB2-
positive cells, on which it exerts an effective and selective anti-tumour activity. 
 
A NEW STRATEGY FOR THE EARLY DIAGNOSIS OF RHEUMATOID 
ARTHRITIS: A COMBINED APPROACH. 
Rheumatoid Arthritis (RA) is one of the most common autoimmune rheumatic 
disease, affecting about 0.5% of the world population, but specific tests for its 
diagnosis are lacking. The RF test is considered the basic screen and a diagnostic 
criterion for RA. Conventional tests for RF are based on agglutination reactions, 
detected by nephelometric instruments. It was recently set up a new cytofluorimetric 
immunoassay for the RF detection, the FIDIS Rheuma test. Moreover, in recent 
years an emerging test for RA has been described, the anti-cyclic citrullinated 
peptides (CCP) test. 
These conventional and innovative methods for RF detection were compared, and 
the efficacy of the anti-CCP test for RA diagnosis was evaluated. To this purpose, a 
prospective study was performed on 350 patients.  
FIDIS Rheuma test appeared to be more sensitive (80%) and specific (87%) than 
nephelometric assay (77% and 73%, respectively). On the other hand, the anti-CCP 
antibodies were found to be specific markers of RA disease. On the basis of these 
results, a novel combined approach was planned, to set up an optimal test, exhibiting 
the highest sensitivity and specificity for RA detection. When the FIDIS Rheuma test 
was combined with the anti-CCP test, a significant increase of sensitivity was 
detected. 
The effectiveness of the combined test (FIDIS Rheuma test / anti-CCP assay) was 
confirmed by statistical analyses. A difference among the diagnostic tests for RA 
diagnosis was found to be significant (p-value<0.05) when the two methods (FIDIS 
Rheuma and anti-CCP) were used in combination. 
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 SOMMARIO 
 
PROGETTO A: ANTICORPI TERAPEUTICI 
 
UNA NUOVA MOLECOLA ANTI-CANCRO: L’ANTICORPO 
COMPATTO ANTI-ErbB2 
 
Il mio progetto di ricerca si è incentrato sulla progettazione e costruzione di un nuovo 
immunoderivato dotato di attività tossica nei confronti di cellule tumorali.  
Un alto grado di specificità nel riconoscere le sole cellule cancerose e l’assenza di 
risposta immunitaria nei pazienti trattati sono tra i principali requisiti che un agente 
anti-cancro deve possedere. 
Uno dei principali limiti dei trattamenti convenzionali adottati nelle terapie del cancro, 
quali la chemioterapia e la radioterapia, è l’assenza di specificità nell’indurre la morte 
delle sole cellule tumorali. In particolare, l’uso di farmaci citotossici può risultare 
dannoso a causa degli effetti collaterali provocati sulle cellule normali, soprattutto 
quelle che in certi organi e tessuti si riproducono attivamente. 
Tra le nuove terapie adottate per la cura del cancro, chiamate anche terapie 
biologiche, una delle più promettenti è senza dubbio l’immunoterapia, ovvero 
l’insieme di trattamenti basati sull’utilizzo di componenti del sistema immunitario, 
quali anticorpi monoclonali o citochine. Tali molecole possono agire sia modulando 
l’attività del sistema immunitario, ovvero inducendo una più efficiente risposta 
immune effettrice nei confronti delle cellule tumorali, sia fungendo da “proiettili 
magici”, come avviene nel caso degli anticorpi monoclonali. Infatti, dato l’alto grado di 
specificità nel riconoscimento dell’antigene, gli anticorpi rappresentano potenziali 
agenti selettivi per le cellule tumorali. Inoltre, se ad essi sono legate molecole 
citotossiche, i risultanti anticorpi coniugati (immunotossine) possono funzionare da 
veicoli in grado di dirigere selettivamente la loro componente tossica verso le cellule 
neoplastiche. 
Nell’immunoterapia dei tumori, estrema importanza riveste la scelta del bersaglio 
verso cui indirizzare gli anticorpi ricombinanti prodotti. A questo proposito, negli ultimi 
anni sono stati isolati e caratterizzati diversi antigeni di superficie detti TAA (antigeni 
associati a tumori). Essi sono proteine espresse ad elevati livelli e presenti sulla 
superficie di cellule tumorali: per tali motivi possono essere considerati marcatori 
tumorali.  
Tra i TAA noti, il recettore transmembrana tirosina chinasico (RTK) ErbB2, omologo 
del recettore del fattore di crescita epidermica (EGFR), risulta essere un promettente 
bersaglio per una terapia anti-cancro. Esso, infatti, è espresso ad elevati livelli (fino a 
2x106 molecole per cellula) sulla superficie cellulare di carcinomi della mammella, 
dell’ovaio e del polmone. Nei tessuti normali, invece, il recettore è normalmente 
assente o espresso a bassi livelli solo su determinati tipi di cellule epiteliali.  
Per le caratteristiche di questo TAA, che lo rendono idoneo come bersaglio per 
l’immunoterapia, in diversi laboratori sono state preparate molecole anticorpali dirette 
contro ErbB2. Tra queste citiamo Herceptin, una versione umanizzata di un anticorpo 
monoclonale murino anti-ErbB2, che attualmente viene impiegato per il trattamento 
del cancro della mammella. 
Esistono però delle difficoltà correlate all’impiego di anticorpi nella terapia 
farmacologica. I principali ostacoli riguardano le caratteristiche fisiche proprie degli 
anticorpi. Infatti, avendo un peso molecolare di circa 155 kDa, gli anticorpi mostrano 
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 una prolungata permanenza in circolo, rendendo probabile il determinarsi di reazioni 
immunogeniche; inoltre la loro taglia molecolare può determinare una limitata 
capacità di diffusione nelle masse tumorali. 
Progressi in tale campo si sono ottenuti con l’isolamento di porzioni più piccole di 
anticorpo che conservano ancora la capacità di legare l’antigene: gli scFv (single 
chain variable fragments). Essi sono costituiti dal dominio variabile della catena 
pesante e di quella leggera legati tra loro da un oligopeptide flessibile; essi hanno un 
peso molecolare di soli 25 kDa. Inoltre, attualmente è possibile ottenere scFv 
interamente umani, attraverso la metodica del phage-diplay, grazie alla quale, da 
genoteche combinatoriali, contenenti tutte le possibili combinazioni di geni VH e VL 
umani, si può ottenere l’espressione degli scFv sulla superficie di virus batterici, i 
fagi. 
Di recente, nei laboratori dei Proff. Giuseppe D’Alessio, Renata Piccoli e Claudia De 
Lorenzo, è stato isolato un frammento anticorpale (scFv) interamente umano 
specifico per il recettore ErbB2 da un archivio fagico, mediante selezione dei fagi con 
cellule eucariotiche integre esprimenti ErbB2 ad elevati livelli. L’scFv umano anti-
ErbB2, isolato in forma omogenea e denominato Erbicina, è risultato possedere le 
seguenti proprietà: è capace di legare le sole cellule che esprimono il recettore 
ErbB2 sulla loro superficie, e di venire in esse internalizzato; è capace di inibire la 
fosforilazione del recettore, a seguito del legame con esso; possiede un’attività 
antiproliferativa nei confronti delle sole cellule tumorali che esprimono il recettore 
ErbB2.  
La natura monovalente del frammento anticorpale ne limita però l’impiego in vivo per 
applicazioni terapeutiche.  
Pertanto, lo scopo del mio lavoro di ricerca è stato quello di trasformare l’scFv in una 
molecola anticorpale di dimensioni maggiori, mediante fusione dell’scFv con la 
regione Fc di una IgG umana. Tale nuova molecola è stata definita “anticorpo 
compatto” per le sue caratteristiche strutturali, essendo esso una molecola 
anticorpale, ma con dimensioni ridotte rispetto alle immunoglobuline. Il vantaggio di 
tale immunoderivato è che esso conserva la specificità di legame dell’scFv da cui 
deriva, ma acquisisce vantaggiose proprietà, caratteristiche di un anticorpo, come la 
bivalenza del sito di legame, il prolungato tempo di emivita in circolo e le funzioni 
proprie della porzione Fc, quali l’attivazione del complemento e di altri componenti 
del sistema immunitario. 
Per generare l’anticorpo compatto anti-ErbB2, la fusione dell’scFv Erbicina alla 
porzione Fc di una IgG umana è stata effettuata utilizzando tecniche di ingegneria 
proteica. Il cDNA codificante l’scFv Erbicina è stato clonato nel vettore di espressione 
eucariotico pIgPlus Signal, contenente il frammento Fc umano. Il vettore 
ricombinante è stato amplificato in cellule batteriche di E.coli JM101 e 
successivamente utilizzato per trasfettare cellule eucariotiche della linea CHO 
(Chinese Hamster Ovary).  
Mediante analisi elettroforetiche e saggi ELISA, condotti con un anticorpo primario 
anti-Fc umano, sono stati individuati i cloni di cellule secernenti l’anticorpo compatto 
nel mezzo di coltura.  
Quindi, è stata effettuata una coltura cellulare su larga scala, per ottenere l’anticorpo 
compatto in quantità utili per le successive analisi strutturali e funzionali. 
L’anticorpo prodotto dalle cellule e secreto nel mezzo di coltura è stato purificato 
mediante cromatografia di affinità utilizzando una resina funzionalizzata con proteina 
A.  
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 I risultati ottenuti da analisi elettroforetiche e da Western Blotting, effettuato con un 
anticorpo primario anti-Fc umano, hanno confermato la presenza di una singola 
specie molecolare, riconosciuta dall’anticorpo, per la quale è stato calcolato un peso 
molecolare di circa 100 kDa, ovvero il peso molecolare atteso per l’anticorpo 
compatto.  
L’anticorpo compatto è stato denominato Erb-hcAb, laddove il termine Erb fa 
riferimento alla specificità antigenica dell’anticorpo, diretto verso il recettore ErbB2, e 
la sigla hc si riferisce alle caratteristiche proprie di tale molecola, essendo appunto 
un anticorpo di natura interamente umana, ma di taglia più compatta (100 kDa) 
rispetto a quella di un anticorpo intero (155 kDa). 
Avendo ottenuto Erb-hcAb in forma omogenea, si è proceduto alla caratterizzazione 
della nuova molecola. Erb-hcAb è risultato possedere le seguenti proprietà: 
• l’anticorpo compatto, come atteso, è espresso come dimero, ovvero risulta 
costituito da due catene polipeptidiche legate fra loro mediante un ponte 
disolfurico; 
• esso lega selettivamente e ad alta affinità le cellule che esprimono il recettore 
ErbB2 sulla loro superficie, mentre non è in grado di legare cellule che non 
esprimono il recettore, come dimostrato da saggi ELISA; 
• La costante di dissociazione dell’anticorpo Erb-hcAb per il recettore ErbB2 è 
risultata pari a 1 nM, valore che conferma l’elevata affinità di legame tra 
l’anticorpo compatto e il suo antigene naturale; 
• L’anticorpo compatto presenta un’affinità per il suo antigene addirittura 
maggiore di quella determinata per Herceptin, saggiato come controllo. 
L’elevata affinità dell’anticorpo per il suo antigene è da mettere in relazione con il 
fatto che l’scFv Erbicina è stato isolato dalla popolazione fagica mediante selezione 
su cellule vitali, piuttosto che utilizzando il recettore purificato. Questo ha consentito 
di selezionare un scFv capace di riconoscere l’antigene nella sua conformazione 
nativa, così come si presenta sulla superficie delle cellule bersaglio.  
Sono stati quindi effettuati saggi per valutare l’effetto dell’anticorpo compatto sulla 
proliferazione di cellule tumorali. A tale scopo è stato utilizzato un sistema di cellule 
in coltura, costituito da cellule ErbB2-positive (cellule SKBR3 da carcinoma 
mammario) ed ErbB2–negative (cellule A431 da carcinoma epidermoide). Si è potuto 
osservare che Erb-hcAb inibisce fortemente ed in maniera selettiva la proliferazione 
delle cellule che esprimono il recettore ErbB2 sulla loro superficie, mentre non si 
sono evidenziati effetti sulla proliferazione di cellule tumorali non esprimenti il 
recettore ErbB2.  
Sulla base dei promettenti risultati ottenuti sull’attività biologica in vitro del nuovo 
immunoderivato Erb-hcAb, ho eseguito un’analisi di tipo bioinformatico volta alla 
costruzione di un modello predittivo della struttura tridimensionale dell’scFv Erbicina, 
che rappresenta il dominio dell’anticorpo compatto deputato a legare l’antigene. La 
comprensione della struttura di tale dominio, infatti, è importante sia per chiarire la 
topologia del sito di legame per l’antigene, sia per la possibilità di effettuare futuri 
studi di protein design finalizzati a migliorare ulteriormente le caratteristiche di tale 
anticorpo. Questi studi sono stati condotti nel laboratorio della Prof.ssa Anna 
Tramontano dell’Università di Roma “La Sapienza”. 
I risultati ottenuti in questo progetto di ricerca sono da inquadrare nell’ambito dei 
recenti successi terapeutici nella cura del cancro, conseguiti utilizzando molecole 
anticorpali. Tali successi hanno incrementato l’interesse della comunità scientifica nei 
confronti di questa classe di proteine ed hanno portato ad un aumento del numero di 
anticorpi in fase di sperimentazione per diverse patologie.  
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 I nostri risultati hanno dimostrato che Erb-hcAb:  
? È un immunoderivato interamente umano, per il quale ci si attende una 
ridotta o nulla immunogenicità nell’uomo 
? Lega con elevata affinità uno dei più specifici marcatori tumorali, il 
recettore ErbB2 
? Inibisce selettivamente la crescita di cellule tumorali esprimenti il recettore 
ErbB2. 
Pertanto i nostri risultati hanno evidenziato che Erb-hcAb è un nuovo promettente 
agente anti-tumorale, ed un potenziale candidato per l’immunoterapia dei tumori.  
L’anticorpo Erb-hcAb è coperto da brevetto (Patent PCT/EP02/07671 on “Human 
mini-antibody cytotoxic for tumour cells which express the ErbB2 receptor” 
G.D’Alessio, R.Piccoli, C. De Lorenzo, D.B. Palmer, M.A. Ritter, owned by Biotechnol 
S.A., Oeiras, Portugal). 
 
 
 
 
PROGETTO B: ANTICORPI PATOLOGICI 
 
UNA NUOVA STRATEGIA PER LA DIAGNOSI PRECOCE 
DELL’ARTRITE REUMATOIDE: UN APPROCCIO COMBINATO 
 
L’Artrite Reumatoide (AR) è una malattia autoimmune cronica che causa 
l’infiammazione delle articolazioni diartodiali, ovvero quelle rivestite da membrana. Le 
malattie autoimmuni si manifestano quando il sistema immunitario dirige la sua 
azione verso costituenti del proprio organismo, e ciò avviene principalmente 
attraverso la produzione di auto-anticorpi diretti verso auto-antigeni cosiddetti “self”. 
L’AR è una malattia sistemica, in quanto può interessare non solo le articolazioni, ma 
anche tessuti e organi interni, conducendo spesso all’invalidità. Circa lo 0.5% della 
popolazione mondiale è affetta da questa patologia. La sua eziologia è sconosciuta, 
ma si ritiene che diversi meccanismi patogenici concorrano al suo sviluppo; uno di 
questi è sicuramente la formazione di immuno-complessi tra auto-anticorpi ed auto-
antigeni solubili. 
Come molte malattie autoimmuni, anche l’AR mostra un andamento rapidamente 
progressivo, qualora non venga stabilito un adeguato protocollo terapeutico. Alla luce 
di queste considerazioni, risulta evidente che una diagnosi precoce è fondamentale 
per prevenire il danno articolare permanente e per modificare il decorso clinico della 
malattia. 
Nel 1987 l’American College of Rheumatology (ACR) ha stabilito i criteri per la 
diagnosi dell’artrite reumatoide. Fra questi criteri è inclusa la presenza nel siero di 
pazienti del fattore reumatoide ad un livello elevato. 
Il Fattore Reumatoide (RF) è una popolazione di auto-anticorpi, prevalentemente di 
classe IgM, diretti contro vari epitopi posti nel dominio Fc delle IgG umane.   
Il RF è considerato anche uno dei fattori scatenanti i danni tissutali, in quanto gli 
immuno-complessi formati da RF-IgG si depositano a livello delle articolazioni, 
promuovendo il processo infiammatorio locale e il conseguente danno tissutale. 
Per queste ragioni, il test diagnostico per la determinazione del RF serico è 
considerato il primo esame da effettuarsi in caso di sospetta AR, ed elevati livelli di 
RF nel siero sono un indice di prognosi negativa per il paziente. 
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 Attualmente vengono di norma utilizzati due metodi di determinazione del RF serico: 
il test di agglutinazione di Waaler-Rose e il test nefelometrico. 
In entrambi i metodi, il siero del paziente viene miscelato con eritrociti di pecora 
rivestiti da IgG di coniglio (Waaler-Rose), oppure con particelle di latex rivestite da 
IgG umane (nefelometria). La presenza di RF nel siero induce la formazione di 
immuno-complessi che danno origine ad agglutinazione. La reazione di 
agglutinazione viene misurata con uno speciale apparecchio turbidimetrico, 
denominato nefelometro.  
Di recente è stata introdotta una nuova tecnologia per la misura del RF serico, il 
FIDIS Rheuma test, che si basa sulla citofluorimetria a flusso.  
Il sistema FIDIS utilizza la tecnologia Luminex, che comprende una miscela di 100 
differenti tipi di microsfere fluorescenti di polistirene, tutte di uguali dimensioni, 
rivestite dall’antigene, un citometro a flusso interfacciato con un sistema di 
digitalizzazione dei segnali ed un hardware e un software per l’elaborazione dei dati. 
Tuttavia, il test del RF non è altamente specifico per l’artrite reumatoide. Infatti è 
possibile riscontrare, anche a titoli elevati, la presenza di questo auto-anticorpo nel 
siero di soggetti affetti da altre malattie autoimmuni, oppure in pazienti affetti da 
infezioni croniche e addirittura in soggetti sani, specialmente in età avanzata. 
Da pochi anni è stato identificato un nuovo gruppo di auto-anticorpi specifici per 
l’artrite reumatoide, gli anticorpi anti-proteine citrullinate (ACPA), che sono stati 
riscontrati per la prima volta nella liquido sinoviale di pazienti affetti da AR. 
La citrullinazione è una modifica post-traduzionale, ad opera dell’enzima peptidil-
arginina deimminasi (PAD), che determina la sostituzione del gruppo imminico 
dell’arginina con un gruppo carbonilico, il cui atomo di ossigeno è il determinante 
antigenico di tali auto-anticorpi. Attualmente, la determinazione degli anticorpi ACPA 
viene effettuata mediante un test ELISA, in cui l’antigene è costituito da un peptide 
citrullinato ciclico (anti-CCP test). 
L’enorme importanza di una diagnosi precoce per l’artrite reumatoide rende 
necessaria la progettazione di un test altamente specifico e sensibile per la rapida 
individuazione della malattia. 
Sulla base di queste considerazioni, lo scopo del mio progetto di ricerca è stato 
quello di confrontare i metodi diagnostici attualmente in uso per la determinazione 
del RF serico e, parallelamente, di valutare l’efficacia degli anticorpi anti-citrullina 
nella diagnosi precoce dell’artrite reumatoide. 
A tale scopo, ho effettuato uno studio prospettico su una popolazione di 350 pazienti 
appartenenti a quattro categorie: 100 pazienti affetti da RA; 100 pazienti affetti da 
epatite cronica associata ad HCV; 53 pazienti affetti da altre malattie autoimmuni e 
97 soggetti sani, come popolazione di controllo. L’intera popolazione è stata 
sottoposta al test per la determinazione del RF serico, sia mediante il convenzionale 
test nefelometrico sia mediante il nuovo saggio citofluorimetrico FIDIS. Inoltre, in tali 
pazienti è stato determinato anche il titolo degli anticorpi anti-CCP mediante saggi 
ELISA. 
I risultati dello studio hanno evidenziato che il metodo FIDIS Rheuma appare più 
sensibile del metodo nefelometrico nella determinazione del RF, in quanto identifica il 
3% in più di pazienti affetti da artrite reumatoide. Inoltre, FIDIS Rheuma è risultato 
anche più specifico del test nefelometrico, in quanto nelle altre categorie di pazienti 
(HCV, C e H) identifica una percentuale minore di falsi positivi al test. 
Il metodo citofluorimetrico FIDIS Rheuma, dunque, ha mostrato una maggiore 
sensibilità (80%) e specificità (87%) rispetto al metodo nefelometrico (rispettivamente 
pari al 77% e 73%), per il dosaggio serico del RF. 
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 E’ stato inoltre confermata l’elevata specificità diagnostica degli anticorpi anti-CCP 
nella diagnosi dell’AR, in quanto tale marcatore è stato identificato soltanto nel 
gruppo di pazienti affetti da artrite reumatoide. 
Sulla base di questi risultati, è stata proposta una nuova strategia diagnostica che 
prevede l’uso del test FIDIS Rheuma combinato a quello anti-CCP, allo scopo di 
approntare un saggio diagnostico che mostri la massima specificità e sensibilità nella 
diagnosi precoce dell’artrite reumatoide. 
Con tale approccio combinato è stata quindi analizzata la popolazione di pazienti 
descritta precedentemente. I risultati hanno indicato che tale test presenta la 
massima sensibilità (100%) e la più alta specificità finora riscontrata (87%) nella 
diagnosi di AR. 
L’efficacia del test combinato FIDIS Rheuma-anti-CCP è stata confermata anche da 
analisi statistiche, che hanno dimostrato che la differenza fra i dati ottenuti con i 
metodi diagnostici sopra riportati assume un valore significativo (p-value <0.05) 
soltanto se viene utilizzato il sistema combinato FIDIS Rheuma test - anti-CCP test. 
Dall’analisi dei dati si può quindi affermare che, nella diagnosi precoce dell’AR, il 
metodo di dosaggio del RF da preferire è quello basato sulla tecnologia 
citofluorimetrica FIDIS. Se a tale marcatore si associa anche il dosaggio degli 
anticorpi anti-peptidi ciclici citrullinati (anti-CCP), si incrementa la specificità 
diagnostica nei primissimi stadi della malattia, e si ottiene un validissimo ed efficace 
strumento diagnostico per l’artrite reumatoide. 
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 INTRODUCTION 
 
PART A. THERAPEUTIC ANTIBODIES 
 
Conventional anticancer treatments, such as surgery, radiation and chemotherapy, 
being characterised by the lack of tumour cell specificity, not only may fail to cure the 
majority of neoplastic disease, but their employments also leads to severe and 
debilitating side effects. Another limit of anticancer therapies is the onset of the multi- 
drugs resistance phenotype (MDR). Cells that express MDR phenotype are able to 
maintain low levels of the anticancer drugs, such as alkaloids or antibiotics (1-2). The 
generally accepted mechanism of multi-drug resistance is that the MDR proteins 
actively expel the cytotoxic drugs from the cells, maintaining the drug levels below a 
cell-killing threshold. Different tumours with MDR protein over-expression often show 
primary (or intrinsic) resistance to cancer chemotherapy. In addition, cancer 
chemotherapy itself might induce the over-expression of these proteins, so that the 
multi-drug resistant clones become less sensitive to chemotherapy (secondary drug 
resistance). 
In the last few years, researchers, investigating alternative therapeutic strategies to 
chemotherapy, have developed new tools for cancer therapy. Among the newly 
acquired tools, immunotherapy represents a new and powerful weapon in the arsenal 
of anticancer treatments.  
 
IMMUNOTHERAPY 
 
Immunotherapy is an anticancer treatment that uses molecules involved of the 
immune system to fight disease, including cancer. This can be done in two ways:  
• by stimulating the immune system to work harder or better;  
• by using components of the immune system, such as recombinant antibodies 
or cytokines. 
The concept of immunotherapy is based on the body's natural defence system, which 
protects us against a variety of diseases. For many years, physicians believed that 
the immune system was effective only in combating infectious diseases caused by 
invading agents as bacteria and viruses. More recently, it has been showed that the 
immune system may play a central role in protecting the body against cancer and in 
combating cancer cells that have already developed. This latter role is not well 
understood, but there is evidence that in many cancer patients, the immune system 
slows down the growth and spread of tumours. One immediate goal of research in 
cancer immunology is the development of methods to harness and enhance the 
body's natural tendency to defend itself against malignant tumours.  
Immunotherapy of cancer began about one hundred years ago when Dr. William 
Coley, at the Sloan-Kettering Institute, showed that he could control the growth of 
some cancer cells and cure a few advanced cancers with injections of a mixed 
vaccine of streptococcal and staphylococcal bacteria known as Coley's toxin. The 
tuberculosis vaccine, Bacillus Calmette-Guerin (BCG), developed in 1922, is known 
to stimulate the immune system and is now used to treat bladder cancers. 
Many years of research have produced different successful examples of 
immunotherapies for cancer. Sometimes referred to as biological therapies, these 
new treatments, such as interferon and other cytokines, monoclonal antibodies, and 
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 vaccine therapies, have generated renewed interest and research activity in 
immunology (Fig.1). 
 
 
          A                                                               B 
    
 
Figure 1. A: Scanning electron microscope picture showing a fully intact breast 
cancer cell surrounded by the immune systems killer T cells. The cancer cell is 
surrounded and attacked by the killer T Cells of the immune system. From 
LEPG, University of Tours, www.lepg.univ-tours.fr B: Molecular model of an 
immunoglobulin.  
 
 
Promising immunotherapeutic agents are represented by monoclonal antibodies 
(mAbs). This is based on the evidence that antibodies can be specifically directed to 
target cancer cells (3), where they may induce direct cytotoxic effects such as Fc-
mediated cellular cytotoxicity. Furthermore, they can target into cells cytotoxic 
molecules. 
As therapy for cancer, monoclonal antibodies can be used to seek out the cancer 
cells, potentially leading to the disruption of cancer cell activities or to the 
enhancement of the immune response against the cancer (4). This strategy has been 
of great interest since the original invention of monoclonal antibodies in the 1970.  
Researchers have experimented different strategies to link cytotoxic drugs, toxins, or 
radioisotopes to monoclonal antibodies, to enhance their effectiveness against 
cancer cells. In this case, the antibodies would function with a targeted delivery 
mechanism; the result would be like a "guided missile", capable of seeking out a 
specific target, such as a cancer cell.  
Studies are in progress to generate Ig-derived molecules to be used as 
immunotherapeutic agents, such as immunoliposomes or bispecific antibodies. 
Immunoliposomes have been constructed by conjugation of antibody fragments 
(scFv or Fab) to small sterically stabilised unilamellar liposomes, to create a targeted 
drug delivery vehicle for the treatment of cancer.  
Bispecific antibodies are able to bind with their Fab regions both their antigen and a 
conjugate molecule or an effector cell. They are used for selective recruitment of an 
effector mechanism to a defined disease-related target structure. Thus, bispecific 
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 mAb serve as mediators (adaptors) of the interaction of an effector to its target 
(Fig.2). 
 
 
 
 
Figure 2: Cancer immunotherapy. ADEPT, antibody directed enzyme prodrug 
therapy; ADCC, antibody dependent cell-mediated cytotoxicity; CDC, complement 
dependent cytotoxicity; MAb, monoclonal antibody; scFv, single-chain Fv 
fragment. From: www.biocrawler.com 
 
 
The development of hybridoma technology and the advances in monoclonal antibody 
production have revitalised the Paul Ehrlich’s ideas concerning the existence of 
cancer cell-targeted, specific “magic bullets” (5). Paul Ehrlich at the beginning of the 
20th century postulated that, if a compound could be made that selectively targeted a 
disease-causing organism, then a toxin for that organism could be delivered along 
with the agent of selectivity. 
 
 
ANTIBODY ENGINEERING TECHNOLOGY 
 
Hybridoma Technology 
About thirty years ago, scientists recognised that antibodies could be created in the 
laboratory, and could potentially function as a powerful tool for the treatment of many 
diseases. The process of producing monoclonal antibodies (hybridoma technology) 
was performed by Georges Kohler, César Milstein and Niels Kaj Jerne in 1975 and 
they shared the Nobel Prize in Physiology in 1984 for the discovery (6).  
The key idea was to use a line of myeloma cells that had lost their ability to secrete 
antibodies, set up a technique to fuse these cells with healthy antibody-producing B-
cells, and be able to select for the successfully fused cells (Fig. 3). 
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Figure 3: Production of monoclonal antibodies (mAb) by the 
Hybridoma Technology. Immunisation of animals with a selected 
antigen stimulates antibody-forming immune cells to produce a 
range of antibodies with varying specificities and potencies. 
Collections of immune cells are fused with tumour (myeloma) 
cells to produce immortalised hybridoma cells, each with a 
distinctive reactivity. These hybridoma cells are then screened in 
vitro against the antigen of interest, and specific clones are 
isolated by limiting dilution. These cells are grown by clonal 
expansion, and a single population of mAb is harvested. 
 
 
A problem in medical applications is that the standard procedure of producing 
monoclonal antibodies yields mouse antibodies. Mouse-generated monoclonal 
antibodies were often rejected by patients whose immune system recognises them 
as foreign molecules, and elicits a human anti-mouse antibody (HAMA) response. 
This response reduces the effectiveness of the antibody by neutralising the binding 
activity and by rapidly clearing the antibody from circulation in the body. The HAMA 
response can also cause significant toxicity upon multiple administrations of mouse 
antibodies. Subsequent generations of antibodies have been re-engineered to 
address these immunogenic complications, resulting in monoclonal antibodies that 
have a higher content of human sequences. 
 
Chimeric Antibodies 
Advance in antibody therapeutics occurred in the early 1980s, when recombinant 
DNA technology was applied to antibody design to reduce the antigenicity of murine 
and other rodent-derived monoclonal antibodies. By this approach, antigenicity could 
be reduced to permit multiple dosing, without affecting antibody affinity and half-life. 
Chimeric antibodies were developed, in which the constant domains of human IgGs 
were combined with murine variable regions by transgenic fusion of the 
immunoglobulin genes (7).  
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 Generally, chimeric antibodies contain approximately 33% mouse sequence and 
67% human sequence. The use of these constructs substantially reduced HAMA 
responses, although it wasn’t able to fully eliminate them. In fact, although chimeric 
antibodies are "more human" than monoclonal antibodies, they nonetheless may 
trigger a Human Anti-Chimera Antibody response (HACA response) by the human 
immune system.  
 
Humanised Antibodies 
Scientists then developed CDR-grafted or "humanised" antibodies, i.e. genetically 
engineered antibodies which contain approximately only 5% to 10% of mouse protein 
sequences.  
The original humanisation strategy described by Winter (8), exploited knowledge of 
the solved crystal structure of antibodies to graft rodent complementarity determining 
regions (CDRs) into the defined human frameworks, and to introduce suitable 
mutations in critical framework residues. In brief, the 6 CDRs of the heavy and light 
chains, and a limited number of structural amino acids of the murine monoclonal 
antibody, were grafted by recombinant technology to the CDR-depleted human IgG 
scaffold (see Fig. 4).  
Although this process further reduced, or eliminated, the HAMA responses, in many 
cases, complex antibody design procedures were needed to re-establish the required 
specificity and affinity of the original murine antibody. 
The need to overcome the immunogenicity problem of rodent, chimeric and 
humanised antibodies (Fig. 4) in clinical practice has resulted in a plethora of 
strategies to isolate fully human antibodies.  
 
 
 
A B 
C D 
Figure 4: Schematic representation of mouse (A), chimeric (B), humanised 
(C), and human (D) antibodies.  
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 Recently, the term "fully human" antibody has been used to indicate those antibodies 
derived from human cells, or from transgenic mice, in which mouse antibody gene 
expression is suppressed and effectively replaced with human antibody gene 
expression (Fig. 4). 
Human antibodies are currently produced by the following methods (9): 
• fusion of mouse myeloma cells with human lymphocytes (blast cells fused to 
peripheral blood lymphocytes) 
• immortalisation of human cells by Epstein Barr virus.  
Nevertheless, both methods have limitations.  
Human mouse hybrid cells have a tendency for preferential loss of human 
chromosomes, making them unstable. Similarly, Epstein-Barr virus does not allow 
preferential immortalisation of blasts engaged in antibody response.  
An alternative and easy way to obtain fully human antibody fragments (Fab or scFv) 
is represented by the Phage-display technology (see  Phage display below). 
 
Tumour Associated Antigens (TAA) 
 
The current strategy in cancer immunotherapy research is based on the 
characterisation of new tumour-associated antigens (TAA), i.e. proteins expressed at 
high levels mostly on tumour cell surface. TAA on tumour cells are not qualitatively 
different in structure from antigens found on normal cells, but they are present in 
significantly higher amount. Because of their abundance, they are often shed into the 
bloodstream. Due to the elevated levels of these antigens on tumour cells, they can 
be used as tumour markers, or as targets for cytotoxic agents bound to 
immunotherapeutic agents, such as antibody molecules.  
 
ErbB2 RECEPTOR 
A good candidate as a tumour-associated antigen is ErbB2, a transmembrane 
tyrosine kinase receptor of 185 kDa (Fig. 5), which is structurally related to the 
epidermal growth factor receptor (EGF) (10).  
The crystal structure of a truncated ErbB2 ectodomain is available (Fig. 5).  
                
         
 
Figure 5. A. Crystal structure (2.5 Å) of ErbB2 extracellular domain. B. X-
Ray diffraction structure (3.25 Å) of ErbB2 complexed with a specific 
antibody.  
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 The crystal structure of residues 1-509 of ErbB2 at 2.5 Å resolution (Fig. 5 A) reveals 
an activated conformation similar to that of the EGFR when complexed with its ligand 
and very different from that seen in the unactivated forms of ErbB3 or EGFR (11).  
The solved structure provides a molecular basis to explain the inability of ErbB2 to 
bind known ligands and to form homodimers.  
These data suggested a model in which ErbB2 is in the activated conformation, 
ready to interact with other ligand-activated ErbB-receptors. Actually, ErbB2 appears 
to be the major signalling partner for other ErbB receptors by forming heteromeric 
complexes with ErbB1, ErbB3, or ErbB4 (12).
ErbB receptors are essential mediators of cell proliferation and differentiation during 
embryogenesis and in adult tissues, and their inappropriate activation is associated 
with the development and severity of many cancers. 
ErbB2 is highly expressed in breast, ovary and lung carcinomas (13, 14), as well as 
in salivary gland and gastric tumour-derived cell lines (15, 16). Its over expression, 
which occur most commonly via gene amplification, can reach as many as 2x106 
molecules/cell (see Fig.6). In normal tissues it is expressed at low levels only in 
certain epithelial cell types (17).  
ErbB2 amplification and over expression plays a central role in the initiation and 
progression of human breast cancer, and has been associated with poor prognosis,  
as it potentiates and prolongs the signal transduction cascades elicited by ligand 
activation of other tyrosine-kinase receptor (18, 19).  
Over-expression of ErbB2 may also increase resistance of tumour cells to host 
defences through the evasion of immune surveillance exerted by activated 
macrophages (20).  
The accessibility of ErbB2 on cell surface and its implications in the development of 
malignancy of these tumours, make it an attractive target for immunotherapy (Fig. 6). 
 
 
                
Figure 6: ErbB2 gene 
amplification (21) 
detected by 
fluorescence in situ 
hybridization.  
 
 
 
ANTI-ErbB2 ANTIBODIES 
 
Since the great relevance of ErbB2 receptor in the development and progression of 
various types of cancer, several groups of researchers have used this molecule as a 
target for immunotherapy, and have produced different types of antibodies directed to 
it. 
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 Mouse and rat mAbs against the ErbB2 extra-cellular domain (ECD) wereisolated 
and found to display useful properties for immunotherapy (22). Hudziak and 
colleagues have produced a murine monoclonal antibody (mAb) directed to ErbB2 
ECD (23); this mAb induced endocytosis, specifically inhibited the growth of ErbB2-
over-exressing cells and increased the sensitivity to TNF-α of drug-resistant tumour 
cells. A murine anti-ErbB2 ECD mAb was produced also by Harwerth and colleagues 
(24, 25). This mAb was found to have anti-proliferative activity on cancer cells both in 
vitro and in vivo experiments.  
However, as a consequence of their non-human origin, the use of these all-rodent 
mAbs as immunotherapeutic drugs is limited, due to the development of an anti-
murine globulin immune response by the human host (HAMA). To avoid HAMA 
responses, genetically engineered chimeric human-mouse mAbs and humanised 
versions of rodent antibodies (26) were prepared. The latter molecules are almost 
entirely humans, as they have only the antigen-binding complementarity-determining 
region (CDR) loops derived from rodent antibodies. A humanised version of an anti-
ErbB2 antibody (Herceptin) is currently in use for the treatment of advanced breast 
cancer (27).  
 
Herceptin (Trastuzumab) 
Herceptin is a recombinant humanised mAb, that selectively binds to the ErbB2 
extra-cellular domain (Fig. 7). 
 
 
       
 
 
 
 
 
Herceptin is able to inhibit the proliferation of hu
cells in both in vitro assays and in animals (29). 
that the use of Herceptin, in combination with
chemotherapy, such as cisplatin or anthracycline
these chemical compounds (30, 31).  
However, there are some warnings to the use o
heart failure was found to be associated with 
incidence and severity of cardiac dysfunctions w
 - 18 - Figure 7: Crystal structure of
the extracellular region of 
human ErbB2 complexed 
with the Herceptin antigen-
binding fragment (Fab) at 2.5
A (28).  man ErbB2-over-expressing tumour 
Clinical studies have demonstrated 
 other systemic drugs adopted in 
s, enhanced the cytotoxic effects of 
f this drug, as a severe congestive 
Herceptin administration, and the 
ere particularly high in patients who 
 
 received Herceptin in combination with anthracyclines (27). Therefore, mAb 
engineering technology needs to be greatly improved, to ensure patients safety. 
 
Single Chain Variable Fragment (scFv) 
 
Although the great potential of whole antibody molecules in the treatment of cancer is 
well known, some limitations to the use of engineered antibodies as therapeutic 
agents have been pointed out, such as the development of immune responses 
against humanised mAb and the low efficacy of antibody effector functions due to the 
large size of immunoglobulins (155 kDa), that makes difficult their penetration in solid 
tumour. To avoid these disadvantages, single-chain variable fragments (scFv) have 
been produced (Fig. 8).  
 
 
       A                                                                   B 
            
 
Figure 8 : The structure of a scFv molecule, made up of the variable domains 
VL and VH of the parental antibody, linked to each other by a flexible 
oligopeptide. A. The VL domains are shown in purple, the VH domains in 
blue, the dimerisation domains (helices) in green, hinge regions in yellow, 
linkers connecting VH and VL in orange. The arrow indicates the approach of 
antigen. B. Secondary structures were automatically assigned with the 
Kabsch-Sander algorithm built into the INSIGHT II software. Helices are in 
red, strands in yellow and coil in green. From: www.bioc.uzh.ch 
 
 
 
Single chain variable fragments (scFv) are molecules made up of the variable 
regions of heavy and light chains of immunoglobulins, linked together by a short  
linker. This chimeric molecule retains the specificity of the original immunoglobulin for 
the antigen, despite the removal of the constant regions and the introduction of a 
linker peptide. The antibody fragments, having a small size (27 kDa), are useful tools 
as immunotherapeutic agents, because they can easily penetrate solid tumours, fully 
preserving the specificity of parental antibody. A variety of different molecules (toxins, 
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 radionuclides, chemotherapeutic drugs) have been conjugated to scFvs for selective 
delivery into cancer cells (32).  
The methodology used to produce scFvs includes the hybridoma technology, by 
which whole immunoglobulins are prepared, and recombinant DNA techniques, to 
isolate the corresponding antibody fragments. Nevertheless, scFvs produced using 
the hybridoma technology are murine-derived molecules, and so induce serious side 
effects if they are administrated in patients. 
Recently fully human scFvs have been isolated using the phage-display technology, 
a method based on the construction of large repertoires of human antibody variable 
regions expressed on filamentous phages, and fused to a phage coat protein (33-36). 
 
PHAGE-DISPLAY TECHNOLOGY 
 
Phage display is an in vitro method to produce collections of proteins or peptides by 
the use of bacteria-infecting viruses (phage). Among proteins, human antibody-
derived molecules can be produced. 
Bacteriophages or phages are viruses that infect and reproduce within bacterial cells. 
They are harmless to humans, and are routinely used in molecular biology 
techniques. The non-lytic bacteriophage M13 is used in phage display technology. It 
is shaped like a flexible filaments with a diameter of about 6.5 nm and of 
approximately 900 nm in length (Fig. 9).  
 
 
 
 
Figure 9: M13 bacteriophage 
 
 
 
The single-stranded circular DNA genome of the phage codes for 10 different 
proteins, which are involved in replication, morphogenesis, and formation of the virus 
coat. The virus infects F' episome-bearing bacterial cells by binding to the adsorption 
end to the tip of the F pilus. After retraction of the pilus and penetration of the viral 
genome through the bacterial membrane, the bacterial cell replicates and translates 
the viral genome producing all the proteins necessary for the formation of new virus 
particles.  
G8p is the major coat protein and is present in about 2700 copies. The proximal 
absorption end of the phage is formed by the minor coat proteins g3p and g6p, 
present in 3-5 copies. The adsorption protein g3p has a molecular weight of 43 kDa; 
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 electron microscopic studies revealed that it forms a loop on a stem structure. The N-
terminal domain of g3p is responsible for penetration. The C-terminal domain is 
needed for morphogenesis and membrane anchorage and is hidden in the phage 
envelope. Deficiency of the adsorption protein g3p drastically reduces infectivity. 
The virus assembly takes place in the cytoplasmic membrane where the newly 
synthesised coat proteins are stored. About 100-300 phage are produced during a 
bacterial life cycle. Phage titres of around 1012 can be found in one ml of an overnight 
culture.  
Fusions to the N-terminus of the coat proteins g3p and g8p are used to display 
foreign sequences without affecting phage infectivity. 
George P. Smith first demonstrated in 1985 that it is possible to display DNA 
sequences encoding enzymes fused to g3p. The foreign DNA was inserted into the 
phage genome between the N-terminal domains of gene III, necessary for infection, 
and the C-terminal domain needed for morphogenesis. In subsequent experiments, 
the fusion site was moved to the N-terminus of gene III, which improved infectivity of 
the phage.  
Based on these experiments, libraries displaying peptides of various length, instead 
of gene fragments, were then generated by various groups and successfully applied 
for epitope mapping and for the identification of protein ligands. Consequently, phage 
were used for the display of functional proteins such as antibody fragments (scFv, 
Fab') (Fig. 10). 
 
 
 
Figure 10: Immunoglobulin and antibody fragments. A whole 
immunoglobulin contains two antigen-binding sites in the Fab domain and 
effector functions, such as complement activation and macrophage binding, 
in the Fc domain. Antigen-binding regions are located within the variable 
regions of the heavy and light chains of the Ig (VH and VL). Hypervariable 
amino acid loops, critical for antigen binding are located within CDRs of the 
Fab domain. Antibody-derived molecule can be prepared using the whole 
Fab portion of the Ig (lower left), or by connecting the variable regions of the 
heavy and light chains with a peptide linker, thus forming an scFv molecule 
(lower right). 
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 Phagemid vector are commonly used for phage display. They are vectors containing 
the genes encoding the virus g3p or g8p coat protein, to which the foreign protein is 
fused, as well as bacterial and viral origins of replication.  
To produce phage particles, cells containing the phagemid are rescued with helper 
phage which provides the proteins needed for the generation of phages. Replication 
of the helper phage DNA is less efficient than that of the Phagemid; therefore, only 
the phagemid DNA is packed into the phage particle. Antibodies against virtually any 
antigen can be directly isolated from these libraries by-passing immunisation. 
Furthermore, using B lymphocytes from various organs of human donors (e.g. PBLs, 
spleen, tonsils, bone marrow), the isolated antibody fragments will be entirely human, 
which is of special interest for therapeutic applications.  
Using phage display technology it is possible to further increase the affinity of a 
primary isolated antibody by mutagenesis, chain shuffling or CDR walking and re-
selection on the antigen (affinity maturation) (Fig. 11). 
 
 
      
   
Figure 11: Phage display: 
generation of a phage-
displayed library. A large 
polymerase chain reaction 
(PCR)-derived library of 
rearranged immunoglobulin 
genes (1-2-3), typically 
partial antibody constructs, 
is obtained from human B 
cells and by variable gene (4-
5) rearrangement in vitro. 
This library is introduced (6) 
into the DNA of bacteria-
infecting viruses (phagemid 
vectors) and linked to the 
gene for a surface protein.  
 
 
 
 
Phage display technology allows to produce a huge number of different phages. 
Enormous phage display libraries, expressing ≥ 1010 individual antibodies (many of 
which are very high-affinity), have been generated.  
The incubation of bacteria containing the phage display library with the immobilised 
antigen, makes it possible to select specific scFv gene-containing phages. The 
panning procedure is summarised in Fig. 12. 
Using this technique, a great number of  human antibody fragments (scFv) have 
been produced (37, 38). Among them, human scFv directed towards the ErbB2 
receptor have been prepared. These scFv were selected on the basis of their ability 
to bind to recombinant extracellular domain of ErbB2 (39, 40) or, more recently, to 
live cells (41). Nevertheless, no one of these antibody molecules was found to 
display anti-cancer properties. 
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Figure 12 : Panning selection procedure 
 
 
 
 
Human anti-ErbB2 scFv (Erbicin) 
 
Recently, in the laboratories of Proffs. Giuseppe D’Alessio, Renata Piccoli and 
Claudia De Lorenzo, where I worked, a novel human anti-ErbB2 scFv has been 
isolated from a large phage-display library (108-109 independent clones) (Griffin 1), 
through a double selection strategy, performed on live cells (41).  
This scFv was named Erbicin and showed interesting properties for immunotherapy. 
It binds specifically to ErbB2-positive cells, inhibits the receptor autophosphorylation 
and is internalised in target cells, where strongly inhibits their proliferation (Fig. 13 A-
B). 
These results made Erbicin a good candidate for immunotherapy. 
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Figure 13: Biological properties of scFv Erbicin. A. Binding of Erbicin to ErbB2-positive 
(SKBR3) and ErbB2-negative (A431) cells. SKBR3 cells and A431 cells were tested by 
ELISA assays with increasing concentrations of Erbicin. Human scFv showed an 
apparent binding affinity (KD) of 4 nM. B. Effects of Erbicin on tumour cell growth. Dose-
response curves of ErbB2-positive cells (black symbols), and ErbB2-negative cells 
(empty symbols), treated for 72h with increasing concentrations of Erbicin. 
 
 
 
However, the small size of the scFv, as well as its monovalent nature, could limit its 
use as a therapeutic agent against mammary carcinoma cells. 
To overcome these limitations, we planned to transform the scFv Erbicin in a more 
stable molecule, by fusing it to a human Fc domain. The chimeric construct is 
expected to acquire advantageous properties with respect to either the scFv alone or 
a whole antibody molecule. 
Engineered antibodies, made up of a Fc moiety and a scFv moiety, are called 
“compact Abs”, i.e. antibody molecules containing two intact binding sites for the 
antigen and a Fc region able to elicit immune effector functions.  
The main advantages of a compact antibody can be summarised as follows: 
• molecular size of about 100 kDa (versus 150 kDa of a whole Ab) 
• two binding-sites 
• an expected prolonged retention time in solid tumours 
• a prolonged clearance from the bloodstream 
• effector functions mediated by the Fc domain: ADCC, Antibody-Dependent 
Cellular Cytotoxicity and CDC, Complement-Dependent Cytotoxicity. 
 
Recently, some groups have successfully cloned fusion proteins made up of human 
scFv and Fc fragments (32-34). In yeast Pichia Pastoris a human chimeric protein 
made up of a human anti-ErbB2 scFv and a human Fc domain was obtained 
although in very low yields (42); however, this protein, being glycosilated in yeast 
cells, is unsuitable for therapeutic trials. 
Nevertheless, as glycosilation is essential for the interaction of immunoglobulins to 
the effector cells of the immune system (macrophages), the most suitable expression 
system for Ig-based molecules is represented by mammalian cells. 
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 PART B. PATHOLOGICAL ANTIBODIES IN RHEUMATOID 
ARTHRITIS 
 
 
RHEUMATOID ARTHRITIS 
 
Rheumatoid Arthritis (RA) is a chronic debilitating autoimmune disease of unknown 
aetiology affecting diarthrodial joints. A joint is where two bones meet allowing 
movement of body parts. The joint inflammation of rheumatoid arthritis causes 
swelling, pain, stiffness, and redness in the joints. In a first phase of the disease, 
joints are usually affected asymmetrically; in a second phase they are affected in a 
symmetrical fashion (43-44) (Fig.14). 
 
 
 
 
 
Figure 14: Schematic representation of normal joint (left) and inflamed 
joints (right), occurring in Rheumatoid Arthritis. The inflammation can 
also occur in tissues around the joints. 
 
 
 
In some patients with RA, chronic inflammation leads to the destruction of the 
cartilage, bone and ligaments, causing deformity of the joints. Damage to the joints 
can occur early in the disease and be progressive. The fingers are typically deviated 
towards the little finger (ulnar deviation) and can assume unnatural shapes (45). 
Classical deformities in rheumatoid arthritis are the Boutonniere deformity (Hyper 
flexion at the proximal interphalangeal joint with hyperextension at the distal 
interphalangeal joint), swan neck deformity (Hyperextension at the proximal 
interphalangeal joint, hyper flexion at the distal interphalangeal joint).  
The thumb may develop a "Z-Thumb" deformity with fixed flexion and subluxation at 
the metacarpophalangeal joint (Fig.15). 
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                                        A                                                                B 
   
 
Figure 15: A. X-ray image of a normal hand (left) and of a hand of a patient with 
RA (right). The inflammation, bone erosion, and bone displacement is shown 
in the right side of the figure. B. Hand deformities occurring in advanced 
stages of rheumatoid arthritis. 
 
  
RA is commonly defined as an autoimmune disease. Autoimmunity is caused by an 
immune response to self antigens, which normally should not elicit an immune 
response (46).  The purpose of a normal immune response is to completely eliminate 
invading antigens from the body, and the response stops once the foreign antigens 
have been completely cleared.  However, since the self antigen eliciting an 
autoimmune response is an intrinsic component of the body and usually impossible 
to eliminate, the immune response is sustained.  Such sustained immune responses 
lead to a chronic inflammation and injury to tissues, and usually is lethal. As RA may 
affect multiple organs of the body, it is referred to as a systemic illness and it is 
sometimes called rheumatoid disease.  
The name “Rheumatoid arthritis” is derived from the Greek. “Reumatos” means 
"flowing", and this initially gave rise to the term 'rheumatic fever', an illness that can 
follow throat infections and which includes joint pain. The suffix -oid means 
"resembling", i.e. resembling rheumatic fever. “Arthr” means "joint" and the suffix -itis, 
a "condition involving inflammation". Rheumatoid arthritis appears to have been 
described in paintings, more than a century before the first detailed medical 
description of the disease in 1800 by Landre-Beauvais (47). 
 
Epidemiology. Approximately 0.5% of the world population is affected by 
rheumatoid arthritis. The incidence of RA was estimated to be about 3 cases per 
10,000 individuals per year, but it increases with the age. Women are affected three 
to five times more than men. It is 4 times more common in smokers than non-
smokers.  
 
PATHOGENESIS OF RHEUMATOID ARTHRITIS 
 
The specific cause of this systemic disease is still unknown, as several 
immunopathogenic mechanisms are involved in this autoimmune disease. Patients 
with RA develop an immune response to a self molecule that mimics a foreign 
molecule (molecular mimicry).  
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 For these reasons, RA can be defined as a Type III immune complex disease, which 
involves immune complexes containing auto-antibodies against soluble auto-
antigens. RA may also be defined as a Type IV, T-cell mediated disease, as it 
involves an unknown synovial joint antigen to stimulate T cells and cause tissue 
injury (46). Both factors, immune complexes and T cells, are important for the 
pathogenesis of RA.  
As an immune complex disease, an auto-antibody called rheumatoid factor (RF) 
(schematically shown in Figure 16) has been identified in about 80% of RA patients 
(48). RF is an IgM anti-IgG auto-antibody, taking part in a T-cell dependent B-cell 
response against the Fc portion of IgG. The resulting IgM-IgG immune complexes 
cause tissue damage (Fig. 16). 
 
 
 
 
Figure 16. Schematic representation of the 
structure of a rheumatoid factor (RF) as a 
pentameric immunoglobulin IgM (it can also 
be IgG or IgA). RFs are antibodies that bind to 
the Fc fragments of the host's IgG molecules 
(bottom right of the figure) causing an 
autoimmunity response.
 
 
 
In normal individuals, RF is elicited in normal immune responses to a severe infection 
or immunisation. In RA patients, T cells are stimulated in an antigen-independent 
manner, inducing the production of cytokines to interact with IgG-autoantigen 
complexes and stimulating naïve B cells. Then, B cells produce immunoglobulins, 
including the rheumatoid factor, which binds the Fc fragment of self IgG molecules 
causing inflammation. 
 
Diagnosis. In 1987 The American College of Rheumatology (ACR) has defined in 
details the criteria for the diagnosis of rheumatoid arthritis (49). These criteria include 
the presence in the patient sera of the rheumatoid factor (see below). 
Most rheumatologists agree the earlier RA patients are treated, the better is their 
prognosis. This implies that an early diagnosis is crucial for therapy establishment 
and patient health (50-51). 
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 RHEUMATOID FACTOR (RF) 
The structure of a Fab fragment of a human IgM-RF bound to its auto-antigen (IgG 
Fc domain) was determined for the first time in 1997 by X-ray diffraction at 3.2 Å 
resolution (52), to establish the topology of antigen-antibody interaction (Fig.17).  
 
                                     
 
 Figure 18. Cartilage damages 
due to deposits of immune 
complexes made up of RF linked 
with IgGs.   
Figure 17. Crystal structure of 
the Fab fragment of a patient-
derived IgM rheumatoid factor, 
complexed with a human lgG4 
Fc, at 3.2 Å resolution. 
 
 
 
 
 
 
This was the first structure of an autoantibody−autoantigen complex being resolved. 
The solved structure, identified as 1ADQ in the Protein Data Bank (PDB), revealed 
that the epitope recognised in IgG Fc includes the C 2/C 3 cleft region, and 
overlaps the binding sites of bacterial Fc-binding proteins.  
The antibody residues involved in auto-recognition are all located at the edge of the 
conventional combining site surface, leaving much of the latter available, potentially, 
for recognition of a different antigen. Since an important contact residue is generated 
by a somatic mutation, the mutated structure induces an antigen-driven selection, 
following somatic mutation of germ line genes, in the production of pathogenic 
rheumatoid factors.  
RFs are also part of the pathogenesis mechanism of rheumatoid arthritis. The 
disease process in rheumatoid arthritis involves the presence of deposits of RF 
linked with IgG occurring in various tissues, such as the synovium or joints. These 
complexes interfere with the normal function of the joint and promote local 
inflammation that results in tissue damage, and sometimes damage to blood vessels 
in the affected area (Fig. 18).  
However, it is important to note that the exact role of these antibodies in rheumatoid 
arthritis is not yet fully understood. 
In the 1987 the American College of Rheumatology chose the 95 percentile principle 
for defining the cut-off value of RF test: the absorbance values higher than those 
obtained from RF measurement in 95% of the healthy controls were considered 
positive. 
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 This means that up to 5% of middle-aged healthy blood donors can be expected to 
have a positive RF test. Increasing the cut-off limit, increases the diagnostic 
specificity for RA, but decreases the sensitivity. 
The RF test is considered the basic screen and hallmark for RA. It is considered a 
RA marker since its presence is associated with an increased risk of developing RA 
in people with mild arthritic symptoms. Higher levels are also detected in more 
severe forms of the disease, a condition that is a severe prognostic factor for patients 
(53).  
Approximately 80% of the people with rheumatoid arthritis have positive titres; 20% 
are considered sero-negative, which means they have no detectable RF. So, a 
negative RF does not rule out the existence of RA.  
RF may also occur in patients with other autoimmune conditions, such as systemic 
lupus erythematosus, mixed connective tissue disease Sjögren’s syndrome and 
occasionally scleroderma. The RF test may also be positive in other conditions such 
as chronic active hepatitis or other chronic infection, or in healthy subjects advanced 
in age (54). 
Actually, the amount of rheumatoid factor in blood can be measured in two ways: 
agglutination tests and nephelometric test. 
 
Agglutination tests. Among the agglutination methods routinely used in clinical 
chemistry we distinguish the Waaler-Rose haemagglutination test to identify the IgM 
class RF directed against rabbit antigenic determinants, and the latex agglutination 
test to identify the IgM class RF directed against human antigenic determinants. 
The Waaler–Rose haemagglutination assay (55-56), based on sheep erythrocytes 
coated with rabbit antibodies, was the prevailing method in the past to analyse RF. 
More recently, latex particle agglutination assays have been developed (57).  
In this last methods, the patient blood is mixed with tiny latex beads covered with 
human antibodies (IgG). The latex beads agglutinate if rheumatoid factor (IgM RF) is 
present (Fig. 19). This method is better used as a first-time screening test for 
rheumatoid arthritis.  
 
 
 
              
Figure 19. Principle of the 
agglutination test. The antibody is 
mixed with the particulate antigen 
(blue spheres) coated on solid 
particles (red spheres). A positive 
test is indicated by the 
agglutination of the particulate 
antigen.                                                                          
 
 
Serial dilutions are made up of the sample to be tested for RF (Fig. 20). Then, a fixed 
number of particulate antigen is added. The maximum dilution that gives visible 
agglutination is determined and indicated as the titre. The titre is the reciprocal value 
of the maximal dilution that gives visible agglutination.  
Occasionally, it is observed that, although the concentration of RF is high, no 
agglutination occurs, whereas the sample is diluted, agglutination is detected (See 
Patient 6 in Fig. 20).  
The lack of agglutination at high concentrations of antibodies is called the prozone 
effect and it is due to the excess of antibody resulting in the formation of very small 
complexes that do not clump to form visible agglutination. 
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Figure 20. Quantitative agglutination test. Each spot 
corresponds to a serum dilution. The agglutination 
reaction is represented by big red spot, while small red 
spot correspond to a negative agglutination reaction. 
Patient 6 serum shows prozone effect, due to the high 
RF concentration. The result of the test is the titre that 
is the reciprocal of the maximal dilution that gives 
visible agglutination.   
 
 
Nephelometric tests. This technique is widely used in clinical laboratories because 
of its relatively easy automation (58). It is based on the principle that a dilute 
suspension of small particles will scatter light (usually a laser) passed through it, 
rather than absorbing it (Fig. 21). The amount of scattered light is determined by 
collecting the light at an angle (usually about 70 or 75 degrees).  
 
 
             
Figure 21: Nephelometry. A 
dilute suspension of antigen 
and antibody will scatter 
laser light passed through it, 
rather than absorbing it. The 
amount of scatter is 
determined by collecting the 
light at an angle of about 70 
or 75 degrees.  
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The antibody and the antigen are mixed in appropriate concentrations so that only 
small aggregates are formed, that do not quickly settle to the bottom. The amount of 
light scatter is measured and compared to the amount of scatter obtained from 
known mixtures. The values obtained with unknown samples are determined from a 
standard curve.  
The results of this test are expressed in International Units. Nephelometry units 
indicate how much light is blocked by the blood sample in the tube. A high level of RF 
causes the sample to be cloudy, so less light passes through the tube with respect to 
a low of RF. 
 
MULTIPLEX IMMUNOASSAYS 
 
The main characteristic of autoimmunity determinations is that antibodies 
(autoantibodies) and not antigens were examined.  
Although many laboratories have adopted diagnostic platforms, such as enzyme 
linked immunoassays (ELISA) (58), an emerging diagnostic technology is 
represented by multiplex immunoassays, which are reliable and flexible methods for 
quantitative detection of multiple analytes from a single serum, plasma, tissue culture 
supernatant, or cell lysate (59-60).  
Although this technology provides advantages of high-throughput, there is a clear 
need for standardisation and internal validation before of these assays. However, 
multiplexed testing in the autoimmunity laboratory appears to have a promising 
future, since this technique permits a reduction in analytical time, with enhanced 
accuracy. 
 
FIDIS™ Rheuma 
It was recently employed a new immunoassay for the simultaneous detection of IgM 
RF directed against human and animal IgG. This assay can replace both Waaler-
Rose and nephelometric tests. This method, named FIDIS™ Rheuma (BioMedical 
Diagnostics, Marne La Vallée, France), is a multiplex immunoassay based on a flow 
cytometric measurement of RF serum levels.  
Flow cytometry is commonly used in the clinical laboratory to identify and quantify 
cells bearing a particular antigen. Cells in suspension are labelled with a fluorescent 
tag, by either direct or indirect immunofluorescence, and then analysed by a flow 
cytometer (Fig. 22, A-B). 
 
 
Figure 22 A. Principle of flow 
cytometry. The cells are 
illuminated by a laser beam. 
The amount of laser light that 
is scattered by the cells, as 
they pass through the laser, 
can be measured, and gives 
information on the size of the 
cells. In addition, the laser can 
excite the fluorochromes on 
the cells and the fluorescent 
light emitted can be measured.  
          
A
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B
 Figure 22 B. Data obtained by a flow cytometer. In a one parameter 
histogram, increasing amount of fluorescence (e.g. green fluorescence) is 
plotted on the x axis and the number of cells exhibiting that amount of 
fluorescence is plotted on the y axis. The fraction of cells that are 
fluorescent are determined by integrating the area under the curve. In a 
two parameter histogram, the x axis is reported red fluorescence and the y 
axis green fluorescence. The number of cells is indicated by defining 
areas with different colour intensity.
 
 
 
 
 
 
 
 
 
The FIDIS™ Rheuma Panel utilises the Luminex technology to simultaneously 
detect and quantify IgM-RF.  
The Luminex 100 IS System is the combination of three components: the xMAP 
fluorescent microspheres, bound to the antigen; a flow cytometry-based instrument 
(Luminex 100); the IS 2.3 software, for data acquisition and analysis (Fig. 23). 
 
 
 
 
 
Figure 23. The Luminex 100 IS System includes the Luminex 100 
instrument, the Luminex XY plate handling platform, and the 
Luminex SD sheath fluid delivery system, IS 2.3 software and PC. 
 
 
 
 
 
Assay principle. Each antigen required for the assay is covalently coupled to an 
individual set of microspheres through its surface functional groups. 
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 The different antigens coupled to microspheres are mixed together to constitute the 
final microsphere reagent (Fig.24). 
 
                         
Figure 24. Each colour-coded 
microsphere is coated with a 
specific reagent which will bind to 
its specific analyte.
 
 
In FIDIS™ Rheuma the microsphere reagent consist of a mixture of colour-coded 
microspheres sensitised by one of the following antigens: human Fc fragment or 
animal immunoglobulins. 
The test is performed in a 96-well blank microplate including a filtering membrane at 
the bottom of the wells. In the first step, the sample is distributed in each well 
containing the microsphere mixture. If this sample contains one or more of the 
suspected antibodies, the antibody will bind to the corresponding antigen present on 
the microspheres.   
After incubation, a wash step through a filtration process will remove unbound 
antibodies. A phycoerythrin labelled anti-human IgM conjugate will bind to the 
captured antibodies. The three-step procedure of FIDIS Rheuma is shown in Fig 25.  
 
 
 
 
      
 
 
 
Figure 25. Principle of FIDIS Rheuma test. Step 1, the microspheres are 
mixed with the samples. Step 2, the microwells are washed through a 
filtration unit. Step 3, the secondary antibody, a phycoerythrin-conjugate, is 
added to the mixture. 
 
 
The reaction is then directly measured by the flow cytometer, which categorises each 
microsphere set according to its fluorescence colour, and simultaneously measures 
the average fluorescence emitted by the conjugate (Fig. 26).  
 
 
 
                     
Figure 26. A red diode laser beam classifies 
each set of microspheres on the basis of its 
unique fluorescence intensity (red to orange) 
which allows to identify which analyte is being 
tested. At the same time, a green laser beam 
illuminates the external second fluorescent 
molecule to quantify the specific reaction 
related to each analyte.
1 2 3 
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 A red diode laser beam of the flow cytometer classifies each set of microspheres on 
the basis of its unique fluorescence intensity (red to orange) which allows to identify 
which analyte is being tested.  
At the same time, a green laser beam illuminates the external second fluorescent 
molecule to quantify the specific reaction related to each analyte. 
Many readings are made on each bead set, further validating the results. A 
calibration system allows to express by interpolation the titre of the sample for each 
antigenic specificity. 
 
ANTI-CCP ANTIBODIES 
 
In recent years a novel group of auto-antibodies has been described in RA which 
may have a role in the development of rheumatoid arthritis.  
In 1964 Nienhius and Mandema (61) described the anti-perinuclear factor (APF) 
antibodies, which specifically targets an antigen (the so called perinuclear factor) 
present in the kerato-hyaline granules surrounding the nucleus of human buccal 
mucosa cells. APF is found in sera from 40-90% of patients with established RA, but 
is less common in early RA (27-38%).  
In 1979, Young and co-workers (62) identified the anti-keratin antibodies (AKA) using 
indirect immunofluorescent (IIF) to examine unfixed rat oesophagus cryostat 
sections. Serum AKA are present in 37-59% of RA patients and are sometimes 
detectable before the clinical onset of the disease.  
Finally, recent studies by Schellekens (63), Van Venrooij (64) and Girbal-Neuhauser 
(65) have shown that APF and AKA are antibodies that specifically bind to substrates 
containing citrulline, a post-translational modified amino acid. This modified amino 
acid was found in filaggrin, vimentin, and fibrin from synovial joint fluid of patients 
with established RA (66-67).  
 
Citrullination. Citrullination, or peptidylarginine deimination, is the process by which 
the imino group of the guanidine moiety of arginine is hydrolysed, leading to the 
replacement of the protonated imino group by an oxygen atom (68). When this 
occurs on an arginine present in a protein, the process is generally catalysed by a 
specific enzyme, the peptidyl-arginine deaminase (PAD) (Fig. 27).  
 
 
 
 Figure 27. Deimination of peptidyl-arginine by PAD 
enzyme.  
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 Database searches reveal the existence of several isotypes of human PAD enzymes; 
these enzymes display tissue specific patterns and, in mice, they are stimulated by 
female sex hormones (69). Citrullinated extracellular fibrin in the RA synovium may 
be one of the major autoantigens driving the local immune response, since the 
production of anti-citrullinated filaggrin antibodies was found to occur in the joints 
(70). 
Moreover, the presence of anti-citrullinated protein antibodies (ACPA) predicts a 
more aggressive course of disease with unfavourable outcome (71). 
 
Anti-citrullinated protein antibodies (ACPA). The citrulline moiety is the 
determinant recognised by APF and AKA antibodies. Following the discovery of the 
crucial role of these epitopes, a biochemical test was developed to detect anti-
citrulline antibodies in sera of RA patients.  
In principle, every citrullinated peptide could be used in serological tests to detect 
ACPA (72), so a number of linear peptides containing one citrulline residue were 
developed.  
However, since most linear peptides have shown low specificity for ACPA detection, 
several attempts were made to obtain a specific and reliable test.  
The use of cyclic peptides was found to increase the sensitivity and the specificity of 
the test. Cyclic citrullinated peptides (CCP) have a three-dimensional design that is 
optimally structured for recognition of the antigenic group by the heterogeneous 
population of RA autoantibodies. Actually, the biochemical assay routinely used to 
detect anti-citrullinated proteins antibodies in sera of RA patients, was developed by 
Walther van Venrooij and colleagues (70) as an enzyme linked immunosorbant 
assay (ELISA) named aCCP test. Anti-CCP antibodies were found to be present in 
about 80% of patients with rheumatoid arthritis. 
 
Synthesis and pathogenetic significance of anti-CCP antibodies. Recent data 
suggest that anti-CCP antibodies may be involved in the pathogenetic process of RA 
and that several RA-associated genetic factors might be related to the production of 
anti-cyclic citrullinated peptide antibodies or citrullinated antigens. 
Masson-Bessiere and co-workers found that the levels of IgG antibodies, directed 
towards citrullinated proteins, were several times higher in the pannus tissue than in 
synovial fluid or serum (73). Moreover, B cells from the synovial fluid of RA patients 
with anti-citrullinated protein antibodies spontaneously produce these antibodies, 
while peripheral blood B cells, or B cells from seronegative RA patients, do not (50).  
These results not only suggest an antigen-driven maturation of anti-citrullinated 
protein B cells at the site of inflammation in RA, but also indicate that the production 
of these antibodies is a local process occurring in the inflamed synovium (74).   
Several nuclear and cytoplasmic proteins, during programmed cellular death 
(apoptosis), undergoes post-translational modifications, and were fragmented and 
exposed on blebs membranes (apoptotic bodies).  
Some of these post-translationally modified proteins, during stress-induced 
apoptosis, are the targets of specific autoantibodies in autoimmune diseases (75-76). 
An attractive hypothesis could be the idea that citrullination of arginine residues in 
synovial cells during apoptosis generates an autoimmune response, as a response to 
an altered apoptotic pathway. The citrullinated peptides, derived from citrullinated 
protein fragmentation, being recognised by immune system as foreign components, 
become new autoantigens (77). 
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 AIMS OF STUDY 
 
The aims of my research activity were:  
 
PART A. Construction, purification and characterisation of a new human anti-
ErbB2 immunoagent, named “compact antibody”.  
 
This immunoagent will be generated by fusing the human anti-ErbB2 scFv (Erbicin) 
to a human Fc domain. This immuno-derivative will be directed towards cancer cells 
expressing the ErbB2 receptor, one of the most promising tumour associated 
antigen, hence a good candidate for targeted therapy. The antitumour potential of 
this immunoagent will be analysed. 
Furthermore, the elucidation of Erbicin structure was thought to be of great interest to 
describe in details the antigen binding site of the antibody, as well as to design 
strategies aimed at improving the immunoagent affinity for the ErbB2 receptor. 
Predictive analyses were planned using the homology modelling technique. 
 
Thus, the project can be summarised in the following steps: 
 
1. Construction of the cDNA encoding the human compact antibody, by fusing 
the cDNA sequences encoding the two moieties of the antibody molecule; 
2. Cloning of the chimeric cDNA into a suitable vector and transfection of 
eukaryotic cells; 
3. Expression and purification of the human compact antibody; 
4. Characterisation of the recombinant product by: 
? structural analyses 
? binding assays to ErbB2 receptor on live cells 
? assays of the effects of the compact Ab on tumour cell growth and 
viability. 
5. Prediction of Erbicin scFv structure by homology modelling.  
 
PART B. The definition of a reliable test for rheumatoid arthritis. 
 
Being well known the great relevance of an early diagnosis of rheumatoid arthritis, a 
high-specific diagnostic test, able to predict a recent onset of the disease, and thus to 
prevent joint damage, is required.  
The multiplexed particle-based flow cytometric technology is a new tool for the 
diagnosis of autoimmune diseases, by combining the advantages of conventional 
methods to the possibility to quantitatively determine multiple autoantibodies in the 
same sample, simultaneously and rapidly. 
The aim of this part of my research activity was to assess the diagnostic value of the 
multiplexed technology for the diagnosis of rheumatoid disease, and to evaluate the 
potentiality of the FIDIS Rheuma assay as an effective diagnostic tool, in comparison  
with the conventional nephelometric test for IgM-RF detection. 
To improve the efficacy and reliability of the available tests, we will investigate the 
use of anti-cyclic citrullinated peptide (anti-CCP) antibodies as specific and early 
markers for rheumatoid arthritis.  
The population under study was constituted by 350 donors, belonging to different 
categories. Serum samples will be analysed, and statistically significant data will be 
evaluated to set up a new diagnostic strategy for early RA identification. 
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METHODS 
 
1. Vectors 
 
The vector Signal pIgPlus (R&D Systems, Fig. 28) was used for the expression of the 
human compact antibody in eukaryotic cells. This vector contains the cDNA encoding 
the Fc domain of a human IgG1. The multiple cloning site (MCS), in which the scFv 
Erbicin was cloned between HindIII and BamHI restriction sites, is located upstream 
to the Fc sequence.  
The recombinant vector, consisting of a chimeric scFv-Fc construct, was trasfected 
into chinese hamster ovary (CHO) cells. 
 
 
 
Amp
R 
 
Figure 28. Structural organisation of the eukaryotic expression 
vector Signal pIgPlus. CMV: cytomegalovirus strong promoter; 
CD33: leader sequence for the protein translocation to the 
membrane; MCS: polylinker sequence; Fc IgG1: sequence encoding 
the Fc domain of a human IgG1; BGH Poly A: polyadenilation site of 
BGH gene; fl1 ori: origin of phage replication; SV40: origin of 
replication of SV40 virus; NeoR: sequence responsible for the 
neomycin resistance; ColE1 ori: origin of replication of E.coli; 
AmpR: sequence responsible for the ampicilline resistance.  
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2. Cell lines and antibodies 
 
The following cell lines were used: SKBR3 cell line from human breast cancer; A431 
cell line from human epidermoid carcinoma; Chinese hamster ovary (CHO) cells. All 
cell lines were provided by American Type Culture Collection, Rockville, MD and 
were cultured in RPMI 1640 (Gibco BRL, Life Technologies, Paisley, UK), 
supplemented with 10% foetal calf serum, containing 50 Units/ml penicillin, and 50 
µg/ml streptomycin ( Gibco BRL). 
After transfection with the recombinant vector, CHO cells were grown in medium 
containing 1 mg/ml neomycin or G418 (Sigma).  
The antibodies used were: Herceptin (Genentech, South San Francisco, CA, USA); 
monoclonal anti-human IgG1 (Fc specific, Sigma, St Louis, MO, USA); horseradish 
peroxidase-conjugated goat anti-mouse immunoglobulins (Pierce, Rockford, IL, 
USA); horseradish peroxidase-conjugated goat anti-human affinity-isolated IgG (Fc 
specific) (Sigma). 
 
 
3. Bacterial strains 
 
 E. coli JM101 strain (78) was used for plasmid amplification. 
 
  
4. Bacterial culture 
 
Culture medium LB (Luria-Bertani), used for the bacterial growth, was prepared as 
described by Sanbrook et al (80). The selection of transformed E. coli JM101 cells 
was obtained in the presence of 50 µg/ml ampicilline.  
 
 
5. Chimeric cDNA construction 
 
The cDNA encoding the scFv Erbicin was amplified from vector pHEN2 by PCR, 
using, as forward and reverse primers, oligonucleotides containing at their 5’ end a 
Hind III site or a BamHI site, respectively.  
Oligonucleotides used for the PCR amplification reaction were: 
 
Forward primer: 
5’CCCCCCAAGCTTCAGGTGCAGCTGTTG3’  
(In red is shown HindIII restriction site)  
 
Reverse primer: 
5’AACCGCGGATCCGCACCTAGGACGGTGAG3’ 
(In red is shown BamHI restriction site)  
 
Amplification reactions were performed using Pfx DNA polymerase from Pyrococcus 
(Invitrogen). The final reaction volume was 50 µl. The PCR reaction mixture 
contained: 
• Erbicin cDNA, 20 ng 
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 • Forward and reverse primers, 20 µM each 
• dNTP 0.2 mM 
• MgSO4 1mM 
• Pfx enzyme 5 U 
 
30 amplification cycles were carried out under the following conditions:  
• 2 min denaturing at 95°C 
• 2 min annealing at 55°C 
• 2 min extension at 73°C. 
The amplified products were purified by gel-elution using the “DNA purification 
system” kit (Promega). The isolated product was analysed by electrophoresis on 1% 
agarose gel. 
 
 
6. Bacterial competent cells 
 
Single clones of JM101 E.coli strain were picked up from LB-agar plates and 
inoculated in 5 ml LB medium. Cells were grown at 37°C until they reached 0.5 
OD600nm and were subsequently incubated at 0°C for 10 min. After centrifugation at 
5000 rpm for 5 min, pelleted cells were resuspended  in 50 mM CaCl2 and incubated 
for 20 min at 0°C. After centrifugation at 4000 rpm for 5 min, cells were resuspended 
in 50 mM CaCl2. 
 
 
7. Cloning of the PCR amplified product into the Signal 
pIgPlus expression vector 
 
The PCR amplified chimeric cDNA was then digested with HindIII and BamHI (New 
England Biolabs, Hertfordshire, UK) for cloning into the corresponding sites of 
plasmid Signal pIgPlus (R&D Systems, Minneapolis, USA). Upon cloning, the cDNA 
is positioned downstream to the leader sequence and upstream to the sequence 
coding for the hinge-CH2-CH3 region of a human IgG1 heavy chain constant region. 
The ligation reaction was performed by incubating at room temperature the digested 
scFv cDNA and pIgPlus Signal vector with “Fast-Ligase” enzyme (Promega). After 2h 
incubation, the ligation products were used to transform E.coli JM101 competent 
cells.  
The recombinant vector was purified from E.coli transformed cells using a mini-prep 
kit (Qiagen Valencia, CA) and analysed by restriction analysis on 1% agarose gel 
electrophoresis. The recombinant vector was then amplified in  E. coli JM101 cells 
and fully sequenced to confirm the correct insertion of the scFv cDNA in pIg Plus 
Signal vector.  
 
 
8. Transfection of CHO cells with the recombinant vector and 
expression of the human compact antibody 
 
The chimeric protein was produced by transfecting CHO cells with the recombinant 
vector. Cells, grown in RPMI containing 10% FCS at 70-80% confluence, were 
trasfected with the recombinant vector.  
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 Recombinant pIgPlus Signal vector (5 µg) was incubated for 10 min at room 
temperature with the Superfect reagent (Qiagen, Valencia, CA) in 0.2 ml RPMI 
medium. CHO cells, seeded in 6-well plates at a density of 5x105 /well, were washed 
with  4 ml PBS, detached from the plates with the cell dissociation solution (Sigma), 
and resuspended in fresh RPMI medium containing 10% FCS. The mixture of 
recombinant vector and Superfect reagent was then added to the cells. After 2h 
incubation at 37°C, cells were harvested, extensively washed with PBS and 
resuspended in RPMI containing 10% FCS with antibiotics. Cells were then 
incubated at 37°C for 48h. 
Stable transfectants were selected in the presence of G418 (1 mg/ml). The selective 
medium was renewed every 3-4 days, until visible colonies were formed. After two 
weeks, resistant clones were picked up and transferred to plates containing fresh 
RPMI medium and G418. Expression of Erb-hcAb in the culture medium was 
determined by quantitative ELISA assays (see below). 
To obtain large-scale recombinant protein production, trasfected CHO cells were 
expanded by growing them in 10 cm plates near to confluence in RPMI medium 
containing neomycin, and then were grown for 3-4 days in serum-free medium. 
 
 
9. Purification of human compact antibody by affinity 
chromatography  
 
The recombinant Erb-hcAb antibody, secreted by trasfected CHO cells, was purified 
from the culture medium by affinity chromatography on a protein A-Ceramic hyper D 
F column (Biosepra S.A., Cergy-Saint-Christophe, France). To 300-500 ml of 
conditioned medium, previously clarified by centrifugation at 2000 rpm, 1 M TrisHCl 
at pH 8.0 was added (1/10 of medium volume). The medium was then loaded on the 
column, previously equilibrated in 0.1 M TrisHCl pH 8.0. The column was 
sequentially washed with 10 volumes of 100 mM Tris-HCl, pH 8.0 containing 0.5 M 
NaCl, and 10 volumes of 10 mM Tris-HCl, pH 8.0. The protein eluate, obtained with 
50 mM glycine pH 3.0, was immediately neutralised by adding 0.1 volumes of 1 M 
Tris, pH 8.0. 
 
 
10.  SDS-PAGE and Western blotting analyses of the human 
compact antibody 
 
The purity of the protein eluate was evaluated by SDS-PAGE analysis on 7.5 % 
polyacrylammide gels, following the procedure described by Laemmli (79). Protein 
bands were detected by Coomassie staining. 
The purified protein was analysed by Western blotting by transferring the protein 
species on PVDF membranes (Millipore, Bedford, MA). An anti-human IgG1 (Fc 
specific) antibody (Sigma) was used, followed by a goat anti-mouse horseradish 
peroxidase-conjugated mAb.  
The signal intensity of the reactive bands was quantitatively measured with a 
phosphorimager apparatus (GS-710, Bio-Rad, Hercules, CA). Protein concentration 
was determined using the BCA assays (Pierce), following the manufacturer’s 
instructions. Spectrophotometric determinations at 280 nm using E1% = 13 were also 
performed. 
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11.  ELISA assays 
 
ErbB2-positive SKBR3 cells and ErbB2-negative A431 cells were transferred to U-
bottom microtiter plates (1 x 105 cells/well). After blocking with PBS, containing 6% 
bovine serum albumin (BSA), cells were incubated for 90 min either with the 
conditioned medium or with the purified immunoagent in the ELISA buffer (PBS/BSA 
3%).  
After centrifugation, supernatants were removed and the pelleted cells were washed 
twice in 200 µl of ELISA buffer, resuspended in 100 µl of ELISA buffer, and incubated 
with peroxidase-conjugated anti-human IgG (Fc-specific) antibodies (Sigma). After 1 
hour, the plates were centrifuged and washed three times with ELISA buffer. The 
reaction was developed by adding 3,3’,5,5’-tetramethylbenzidine (TMB) (Sigma) and 
stopped with 1 M HCl. Binding values were obtained by determining the absorbance 
at 450 nm. The reported values are the mean of at least three determinations. The 
standard deviations were below 5%). 
 
 
12.  Cell growth inhibition assays 
 
Cells were seeded in 96-well, flat-bottom plates as follows: SKBR3 cells at a density 
of 1.5 x 104/well; A431 at a density of 5 x 103/well. After the addition of the 
immunoagent under test, viable cells were counted by the Trypan blue exclusion test 
at suitable time intervals (24-48-72 h). Cell survival was expressed as the percentage 
of viable cells in the presence of the protein under test, with respect to control 
cultures grown in the absence of the protein. Typically, cell survival values were 
obtained from at least three independent experiments in which triplicate counts were 
determined. Standard deviations were below 5%. 
 
 
 
13. Molecular Modelling 
 
• CDR (complementarity determining regions) 
The CDR regions were determined using KABAT numbering. The CDR canonical 
loop structures were determined using Chothia description. 
 
• Database search 
Database search for VH (variable heavy chain) and VL (variable light chain) sequence 
homology was performed using the protein Blast (BLASTP) program at NCBI.  
 
• Homology modelling and energy minimisation 
Insight II was used to model VH and VL chains separately. The VH and VL models 
were then connected by a synthetic peptide [(Gly4Ser)3] using BUILDER/Insight II,  
followed by energy minimisation cycles in a CFF91 force field. 
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 14. Patients under test 
 
350 unselected serum samples were tested by a prospective study. Four categories 
of patients were analysed: 
 
1. RA: 100 patients who had been affected by RA 
 
2. HCV: 100 patients who were affected by chronic infection of hepatitis C virus  
 
3. C: 53 patients affected by other connective tissue diseases  
 
4. H: 97 healthy blood donors 
 
Serum samples from each patient were centrifuged and stored at -20°C, until use. 
 
15. Agglutination test  
 
Principles of the Procedure  
Agglutination test for IgM-RF determination was performed using N Latex RF 
automated test (DADE BEHRING), using a nephelometric instrument (BN System, 
DADE BEHRING). 
Polystyrene particles coated with an immuno-complex consisting of human γ-
globulin/anti-human γ-globulins from sheep, were agglutinate when mixed with 
samples containing RF. A beam of light is passed through the aggregates and 
scattered. The intensity of the scattered light is proportional to the concentration of 
analytes (RF) in the sample. The results were evaluated by comparison with a 
standard tested at known concentration. 
 
Assay protocol 
All steps necessary for the assays were performed automatically by the BN System 
instrument. 
Reagents provided by the manufacturer were lyophilised and reconstituted in distilled 
water about 15 minute before use. 
Serum samples were centrifuged prior tests, to avoid interference due to sample 
turbidity. Samples were automatically diluted 1:20 with serum diluent, provided by the 
manufacturer.  
Reference curves were obtained by multi-point calibration. Serial dilutions of RF 
standards were automatically prepared by the instrument. 
 
 
Results interpretation 
Results were expressed in international units per mL (IU/mL) according to the first 
British Standard for Rheumatoid Arthritis. Serum samples >15 U/mL were considered  
positive.
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 16. FIDISTM Rheuma Assay System 
 
Set up of the FIDISTM instrument 
A maintenance procedure has to be daily used, to assure the good performance of 
the system. Firstly, the optic system (laser beam) is warmed up, and this procedure 
requires thirty minutes. Then, any air bubbles in the Fidis microfluidic pathway were 
removed by the “prime” procedure. Then, the probe was  cleaned by repetitive 
washing with isopropanol 70%. The pressure and temperature of the system were 
checked before testing samples. Calibration set-up was performed once per month 
systematically, and a new lot of sheath fluid reagent used, in order to ensure optimal 
instrument performance. Calibration was also performed when the temperature value 
was out of the operation range of the instrument.  
At the end of the analysis session, a sanitization was done, by using 70%sodium 
ipochlorite. 
 
Microspheres 
Each antigen (Fc fragment from human or rabbit IgG) was conjugated by a covalent 
bond to an individual set of microspheres through its surface functional carboxyl 
groups. The coupling procedure (activation, concentration of microspheres, quantity 
of coupling antigen-stabilising solution) was set up to ensure sensitivity of the assay 
and shelf life of the preparation. Following the coupling procedure of each set, the 
two antigen-coupled microsphere sets were mixed generating the final microsphere 
reagent.  
 
Assay procedure 
 
1. Microspheres dispensing. For each assay, a “reagent-blank” well, a positive 
control well, a negative control well, and a calibrator well were required. The 
microsphere reagent has to be mixed vigorously before dispensing 50 µl in 
each well to be used. 
 
2. Samples incubation. 100 µl of TDL buffer, provided by the manufacturer, 
were added to the reagent blank well. 100 µl of ready to use calibrator and of 
prediluted controls and samples were dispensed in the corresponding wells. 
Plates were covered to avoid direct light and incubated for 30 min at room 
temperature. 
 
3. Wash step. Plates were washed with TDL buffer (2 cycles), using the filtration 
unit. 200 µl of TDL buffer were dispensed in all wells. The filtration was 
repeated for, as described above. The residual buffer in the microwells was 
removed by blotting the plates with an absorbent towel. The plates were 
placed on a dry surface prior incubation. 
 
4. Secondary antibody dispensing. 100 µl of prediluted secondary antibody 
conjugated with phycoerythrin were dispensed in all microwells. Plates were 
incubated 30 min at room temperature. 
 
5. Test reading. The excitation system of the FIDIS analyzer includes two solid-
states lasers. A reporter laser excites fluorescent molecules bound to 
biological reactants at the microsphere surface; a classification laser excites 
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 fluorochromes embedded in the microsphere. The laser illuminates the 
microspheres as they file through the cuvette. Photodiodes and photomultiplier 
tube receive fluorescent signal from the microspheres. The analyzer digitises 
the waveforms signals. 
 
6. Results validation. The signal obtained on the calibrator should be over 100. 
The positive control value should be within the range 38-80 IU/ml; the negative 
control less than 25 IU/ml. Cut-off values were determined by the 
manufacturer by using 142 samples tested with the above procedure. A value 
of 30 IU/mL was assigned to the signal corresponding to the cut-off value.  
 
7. Results interpretation. Results were expressed in international units per mL 
(IU/mL), according to the British Standard for Rheumatoid Arthritis (Table 1). 
 
International 
Units (IU/ml) 
25 IU/ml 25-30 IU/ml > 30 IU/ml 
Interpretation Negative Borderline Positive 
Table 1. Reference values for the FIDIS Rheuma test for RF 
detection. 
 
8. Quality control. Internally sourced control samples were used for human and 
animal different specificities. They were: an IgM-RF positive serum for human 
specificity, and an anti-rabbit IgG antibody of IgM class for the animal 
specificity. 
 
 
17. Anti-CCP IgG ELISA Test 
 
The anti-CCP IgG ELISA (Quanta Lite™, Inova Diagnostics, San Diego) is a semi-
quantitative enzyme-linked immunosorbant assay for the detection of anti-CCP 
(Cyclic Citrullinated Peptide) IgG antibodies in patient sera. 
 
Principles of the Procedure  
The antigen used is a synthetic cyclic citrullinated peptide bound to the bottom 
surface of a microwell plate. Pre-diluted controls and diluted patient sera were added 
to separate wells, allowing any CCP IgG antibodies present to bind to the 
immobilised antigen. Unbound samples were washed away and an enzyme labelled 
anti-human IgG conjugate was added to each well. Finally, the enzyme activity was 
measured by adding a chromogenic substrate and measuring the intensity of the 
developed colour.  
 
 
Assay procedure  
 
1. The required number of microwells/strips was placed in the holder.  
2. 100µL of the prediluted CCP IgG ELISA Low Positive, the CCP IgG ELISA 
High Positive, Calibrators B through E, the ELISA Negative Control and the 
diluted patient samples were added to the wells. Samples were analysed in 
duplicate. Wells were covered and incubated for 30 min at room temperature.  
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 3. Wash step: the content of each well was thoroughly aspirated. 300µL of the 
diluted HRP Wash buffer were added to wells, the liquid was then aspirated. 
This sequence was repeated three times. Plates were inverted and tapped on 
an absorbent material to remove any residual fluid after the last wash.  
4. 100µL of the HRP IgG Conjugate were added to each well. Samples were 
incubated for 30 min at room temperature.  
5. Wash step: as in Step 3.  
6. 100µL of TMB Chromogen were added to each well and samples incubated in 
the dark for 30 min at room temperature.  
7. 100µL of HRP Stop Solution were added to each well, and gently mixed.  
8. The absorbance (OD) of each well was read at 450 nm within one hour the 
reaction stop.  
 
Results interpretation 
 
Method of calculation: semi-quantitative results using a standard curve. 
A standard curve was obtained by determining the absorbance values of five 
standard samples (named calibrators, from A to E) supplied by the manufacturer 
(Fig. 29). 
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Figure 29. The standard curve obtained by testing known positive 
samples with anti-CCP ELISA test. 
 
 
Using this standard curve, the anti-CCP IgG concentration of the samples was 
determined by reading the Units on the “Y” axis corresponding to the absorbance 
values on the “X” axis. The test result is classified as negative, weak positive, 
moderate positive or strong positive according to the table below (Table 2).  
 
 
Units (U/ml) < 20 U/ml 20-39 U/ml 40-59 U/ml > 60 U/ml 
Interpretation Negative Weak 
positive 
Moderate 
positive 
Strong 
positive 
Table 2. Reference values for anti-CCP ELISA test. 
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 Internal quality control 
As it is recommended by the GMP (good manufacturing practices) protocol, an 
internally sourced control sample was used for the anti-CCP IgG antibodies. An anti-
CCP positive serum was used as the internal control sample. 
 
 
18. STATISTICAL ANALYSES  
 
All the data obtained using the nephelometric or the FIDIS Rheuma tests on serum 
samples, were analysed by statistical methods. 
Statistical analyses were performed using the computer software R 2.4.1 (The R 
Development Core Team). 
McNemar's test was applied to a 2 × 2 contingency table, where each of the four 
cells contained one of the following samples: “positive with both methods”, “negative 
with both methods”, “positive with referral (nephelometric test) but negative with the 
experimental method (FIDIS Rheuma test)” and “negative with referral but positive 
with the experimental method”, respectively.  
The statistical null hypothesis was that the number of samples recognised as 
“positive” was the same in both methods. In a statistic test, null hypothesis are 
typically statements of no difference. 
The alternative hypothesis was that the number of samples recognised as “positive” 
was higher with the experimental FIDIS Rheuma method.  
Due to the small difference between the two methods, the Yate’s correction factor 
was inevitably applied to the McNemar's test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 - 46 -  
 RESULTS 
 
PART A. THERAPEUTIC ANTIBODIES: A NOVEL 
ANTICANCER IMMUNOAGENT. 
The first phase of my research activity was carried out in the laboratories of Prof. 
Renata Piccoli of the University of Naples “Federico II”, where I worked on a research 
project aimed at the construction of a new anticancer immunoagent. The starting 
point of my research work was represented by Erbicin, a human single chain 
antibody endowed with selective antitumour activity. 
 
A1. THE PRODUCTION OF A NOVEL IMMUNOAGENT: A 
“COMPACT” ANTIBODY. 
 
Construction of the cDNA encoding the anti-ErbB2 human compact 
antibody 
 
To produce a new anti-ErbB2 immunoagent, we fused the sequence encoding the 
scFv Erbicin to that of a human IgG1 Fc domain, generating a so called “compact” 
antibody. In Fig. 30 the schematic representation of the anti-ErbB2 compact antibody 
is reported. 
 
 
scFv 
               
    
Figure 30. Schematic representation of the human compact anti-
ErbB2 antibody. A, Erbicin, the parental anti-ErbB2 scFv. B, a 
human IgG1; C, the compact Ab, named Erb-hcAb. H, the hinge 
region with disulfide bridges. CH2 and CH3 are the heavy chain 
constant domains of a human IgG1. VH and VL are the heavy and 
light chain variable domains, respectively.  
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 The main advantage of a compact antibody is that this IgG-like protein has a 
molecular size lower than that of a whole immunoglobulin, but it contains all 
functional relevant antibody regions.  
The full length cDNA encoding the human anti-ErbB2 scFv Erbicin, cloned in pHEN2 
vector, was amplified by PCR, using as forward and reverse primers, 
oligonucleotides presenting at their 5’ end the HindIII or BamHI  site, respectively 
(Fig. 31).  
 
 
 
 
OriC
AmpR
scFv Erbicin
Lac
HEN2p
HindIII BamH1
scFv
+ Primers
PCR amplification of Erbicin cDNA
 
Figure 31. The cDNA encoding the human anti-ErbB2 
scFv Erbicin was amplified from vector pHEN2 by 
PCR. Hind III and Bam HI  restriction sites were 
inserted upstream and downstream to the coding 
sequence, respectively.  
 
 
 
The PCR amplified fragment was then digested with HindIII and BamHI and cloned 
into the corresponding sites of Signal pIgPlus plasmid, an eukaryotic vector in which 
a human IgG1 Fc domain is cloned downstream to the multiple cloning site (Fig. 28, 
Methods section).  
A leader sequence (CD33) is positioned upstream to the cloning site, useful for the 
recombinant protein secretion. Thus, upon cloning, the eterologous gene is fused to 
the hinge region and to the human IgG1 Fc region, which comprises the CH2 and 
CH3 domains of a human IgG1 heavy chain constant region. The cloning strategy is 
depicted in Fig. 32.  
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Figure 32: The PCR amplified fragment was cloned into the 
corresponding sites of Signal pIgPlus plasmid, downstream 
to the leader sequence CD33, and upstream to a DNA 
sequence encoding the hinge region and the CH2 and CH3 
domains of a human IgG1 heavy chain constant region (Fc). 
 
 
 
 
To amplify the DNA chimeric product, E.coli JM101 competent cells were trasfected 
with the recombinant vector, as the vector Signal pIgPlus contains a bacterial 
replication origin (OriC) and the antibiotic resistance for ampicilline (AmpR).  
Some of the transformed clones were selected on the basis of their ampicilline 
resistance, and grown in LB medium containing the antibiotic. Plasmids were isolated 
from bacteria and then digested with HindIII and BamHI to identify recombinant 
clones. In Figure 33, the results obtained from gel-electrophoresis analysis of one of 
the selected recombinant plasmids are reported.  
A 800 bp fragment was obtained by digestion with HindIII and BamHI (lane 2), 
corresponding to the expected size for the scFv cDNA.   
Sequence analyses confirmed the identity of the chimeric DNA, i.e. a DNA encoding 
an immunoagent consisting of the human anti-ErbB2 scFv fused to a human Fc 
domain. This fully human compact antibody was named Erb-hcAb, where  Erb refers 
to the ErbB2 receptor, i.e. the specific antigen, and hc indicates the human origin (h) 
of the compact (c) Ab.   
In Fig. 30 the structural organization of Erb-hcAb is shown, with the scFv moiety at 
the N-terminal end and the Fc moiety at the C-terminal. The two regions are spaced 
by a human hinge region. 
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                                                    1             2             3 
 
800 bp 
 
Figure 33. Gel-electrophoresis analysis of a 
recombinant plasmid after enzymatic digestion with 
HindIII and BamHI. Lane 1, molecular weight 
standards. Lane 2, digested plasmid. Lane 3, the scFv 
cDNA. The arrow indicates the size of the original 
scFv. 
 
 
 
Expression of Erb-hcAb in eukaryotic cells. 
 
To express Erb-hcAb, we used the eukaryotic expression vector, Signal pIgPlus (Fig. 
28, Methods section), a vector containing the strong and inducible promoter of CMV, 
the leader sequence CD33 that allows efficient secretion of the cloned protein in the 
cell medium, and the neomycin resistance gene for the selection of recombinant 
clones. 
For the expression of the compact Ab Chinese hamster ovary (CHO) cells were 
used, in which the glycosilation pattern of eukaryotic proteins recalls that of human 
cells. 
CHO cells were trasfected with the recombinant Signal pIgPlus plasmid containing  
the Erb-hcAb cDNA. In brief, 70% confluent cells grown in RPMI medium 
supplemented with serum, were trasfected with 5 µg of the expression vector using 
the Superfect reagent. This transfection system consists of activated spherical 
dendrimers that assemble DNA in a compact structure, making the introduction of 
DNA into cells easier. The dendrimer-DNA complexes, being positively charged, are 
able to interact with the negative charges present on cell surface. Cells were then 
incubated for 2 h at 37°C. 
Stable trasfectants were then selected in the presence of 1 mg/ml G418, a neomycin 
analogue aminoglycoside antibiotic. Fifty clones were selected and transferred with a 
sterile handle in 24-microwell plates. 
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 Selection of recombinant clones expressing high levels of Erb-
hcAb by ELISA assays. 
 
ELISA (Enzyme Linked Immuno Sorbant Assay) assays were performed to verify the 
presence of Erb-hcAb in the conditioned medium obtained from recombinant clones, 
and to select clones that express high levels of the fusion protein. 
For the binding assays, living cells expressing the ErbB2 receptor on their surface, 
rather than the isolated antigen, were used as a target. This strategy is highly 
effective, as it allows to test the ability of a ligand to recognise its specific receptor in 
its native conformation. 
As target cells, we used SKBR3 cells from human mammary adenocarcinoma, a cell 
line over-expressing ErbB2 on the cell surface. Cells, harvested using a non-
enzymatic dissociation solution, were washed in PBS buffer and transferred to U-
bottom microtiter plates (1x105 cells per well). Cells were incubated with the 
conditioned medium obtained from each of the 50 selected recombinant clones 
producing Erb-hcAb. After 90 min incubation, cells were extensively washed and 
treated with an anti-human Fc antibody, in order to quantify the amount of the 
recombinant Erb-hcAb able to bind to its antigen on target cells. Finally, goat anti-
mouse HRP-conjugated immunoglobulins were used for the detection of cell bound 
antibodies. After 1 h incubation, the multiwell plates were centrifuged, cells were 
washed and reacted with the TMB substrate. The enzymatic reaction product was 
measured by determining the absorbance at 450 nm. The  absorbance values were 
expressed as the mean of at least three determinations (S.D.≤ 5%). Positive clones 
with absorbance values > 1 O.D. were selected as shown in Fig. 34.  
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production of 
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The conditioned medium obtained from untrasfected CHO cells was used as a 
negative control. As a positive control, cells were incubated with Herceptin, a 
humanised anti-ErbB2 monoclonal antibody.  
Among the clones expressing Erb-hcAb, clone C2 was found to produce the highest 
amount of the compact Ab (see Fig. 34). Clone C2 was transferred in larger plates for 
cell amplification in RPMI medium containing 10% FCS  and G418. 
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 Expression of Erb-hcAb. 
 
Once a single clone was identified as a Erb-hcAb producer (clone C2), a small-scale 
experiment for the production of compact Ab was carried out.  
Cells (1x106) were grown in RPMI with 10% FCS and the antibiotic G418; after 72 h, 
an aliquot of 9 ml of conditioned medium was analysed by affinity chromatography on 
a protein A-agarose  column to select the recombinant antibody. As it is known, 
protein A is able to bind the Fc domain of antibodies, allowing immunoglobulin 
purification and concentration. As a negative control, unconditioned medium was 
used. 
The chromatographic conditions are described in Methods section. The eluted 
fractions were analysed by Western blotting, using an anti-human Fc mAb.  
As shown in Fig. 35, the presence of a protein species corresponding to a molecular 
size of about 100 kDa, i.e. the expected size for Erb-hcAb, was detected in the 
conditioned medium of trasfected cells. A faint band of about 155 kDa was also 
present, presumably due to the IgGs present in the calf serum used for cell growth. 
The 100 kDa species was absent in the unconditioned medium, indicating that the 
protein selected by immuno-affinity chromatography was produced and secreted by 
the cells. 
On the basis of these results, we concluded that a protein species with the molecular 
size expected for Erb-hcAb and recognised by an anti-human Fc mAb, was 
expressed by trasfected CHO cells and secreted in the medium. 
 
 
 
                                                        1                2 
                                               
Figure 35. Western 
blotting analysis of 
the samples 
obtained by affinity 
chromatography of: 
conditioned 
medium of 
trasfected cells 
(lane 1); 
unconditioned 
medium (lane 2).  
155 kDa
100 kDa
 
 
 
Scaling-up of the procedure to isolate the recombinant compact Ab. 
 
On the basis of these encouraging results, a large scale expression of the human 
anti-ErbB2 compact antibody was performed, using the experimental conditions 
described above. 
In order to analyse the effects of serum on Erb-hcAb expression levels, the amount 
of  the recombinant product, obtained in the presence or absence of serum, was 
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 tested. Cells from clone C2 were grown in two plates containing RPMI medium, 1 
mg/ml neomycin, 10% serum, until they reached 70% confluence. Then, the medium 
was replaced with fresh RPMI containing 10% FCS and neomycin (1 plate), or 
neomycin alone in serum-free medium. From the two samples (serum treated or 
untreated), Erb-hcAb was purified by affinity chromatography using a protein A-
Ceramic Hyper D®F column, expected to have higher affinity for antibody species 
than protein A-agarose.  
The experiments were performed as described in Methods section; the eluted 
samples were analysed by SDS-PAGE. The results are reported in Fig. 36. 
As shown in the figure, a single band with the expected molecular mass was 
produced by the cells grown in the absence of serum (lane 1). On the other hand, the 
sample obtained by cells grown in the presence of serum appeared to contain not 
only the recombinant protein, but higher molecular weight species, identified as 
serum IgGs (lane 2).  
Although comparable yields in the two conditions  (2.0 and 1.5 mg/l, respectively) 
were obtained, the procedure in the absence of serum was chosen as the one to be 
routinely used to produce Erb-hcAb, due to the high level of purity of the recombinant 
protein obtained by serum-free expression. 
In conclusion, we set up a one-step purification procedure that allowed us to isolate 
Erb-hcAb as a pure product, with a final yield of 2 mg/l. 
 
 
                                                         1                  2 
 
155 kDa 
100 kDa
 
Figure 36. SDS-PAGE analysis of samples 
obtained  by affinity chromatography of: 
conditioned serum-free medium (lane 1); 
conditioned medium containing serum (lane 2).  
 
 
 - 53 -  
 A2. CHARACTERISATION OF THE COMPACT ANTIBODY 
 
 
Analysis of the quaternary structure of Erb-hcAb. 
 
To verify that Erb-hcAb was correctly assembled in the IgG typical quaternary 
structure, SDS-PAGE analyses were performed (Fig 37). The final construct was 
expected to contain two disulfide bonds located in the hinge region and bridging the 
two identical moieties, each constituted by a scFv molecule fused to a CH2-CH3 
domain.  
Under non-reducing conditions (Fig. 37, lane 2), a single band of about 100 kDa was 
detected. This molecular weight is that expected for a dimeric antibody molecule.  
Under reducing conditions (Fig. 37, lane 3), instead, a single band corresponding to a 
molecular size of about 50 kDa was detected. This indicated that the two subunits 
are linked by disulphide bridges. 
These data demonstrated that the compact antibody is expressed as a disulphide-
linked dimer (See also Fig.30).  
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Figure 37. SDS-PAGE analysis of Erb-hcAb 
under reducing (lane 3) or non-reducing (lane 2) 
conditions. Molecular weight standards are in 
lane 1. 
 
 
 
Binding assays of Erb-hcAb to ErbB2 receptor. 
 
The ability of the compact antibody to bind to the ErbB2 receptor was analysed by 
ELISA assays.  
To this purpose, we used SKBR3 cells from human breast cancer, over-expressing 
ErbB2 on their surface; in parallel experiments A431 cells, from human epidermoid 
carcinoma, were used as ErbB2-negative cells. 
 - 54 -  
 Cells were transferred to U-bottom microtiter plates (1x105 cells/well) and incubated 
in the presence of Erb-hcAb; as a positive control we used Herceptin, the well known 
anti-ErbB2 murine humanised antibody. In parallel experiments, cells were incubated 
with Erbicin, the human anti-ErbB2 scFv, i.e. the scFv used for the construction of the 
compact antibody.  
The results of the ELISA assays are reported in Fig. 38, where the binding curves 
obtained with Erb-hcAb are compared with those of Herceptin and Erbicin.  
 
 
 
 
 
 
Figure 38. Binding assays of different immunoagents 
to the ErbB2-positive SKBR3 cells (black symbols), or 
to ErbB2-negative A431 cells (empty symbols). Cell 
binding was tested using Erb-hcAb (circles), Erbicin 
(rhomboids), or Herceptin (squares). 
 
 
Erb-hcAb was found to be able to specifically bind to SKBR3 target cells. On the 
other hand, the compact antibody did not react with ErbB2-negative cells (A431), as 
also found for Erbicin and Herceptin (see Fig. 38). Interestingly, A431 cells over-
express the ErbB1 EGF receptor, another member of ErbB family. 
These results clearly indicate that the compact antibody fully retains the specificity of 
Erbicin for its antigen. 
The apparent binding affinity of the compact antibody for ErbB2 receptor, i.e. the 
concentration corresponding to half-maximal saturation, was found to be 1 nM. This 
value has to be compared with the binding affinity values determined for Erbicin (4 
nM) and for Herceptin (5 nM).  
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 To directly compare the affinity constants of these immunoagents, it should be 
considered that the compact Ab and Herceptin harbour two antigen binding sites per 
antibody molecule, whereas Erbicin has a unique site. Presumably, the four-fold 
increased avidity with respect to Erbicin is due to the acquired bivalency of Erb-hcAb 
for ErbB2. 
This led us to conclude that the new immunoagent is able to recognise its antigen 
with a similar, if not higher, affinity with respect to the other immunoagents.  
 
Tumour cell growth inhibition assays.  
 
The effect of Erb-hcAb on tumour cell growth was assessed by measuring the 
survival of SKBR3 cells treated with increasing concentrations of Erb-hcAb. The 
results are reported as the percentage of survival of treated cells with respect to 
control cells. 
As shown in Fig. 39, Erb-hcAb was found to inhibit the growth of SKBR3 in a dose-
dependent manner. When compared to the effects of Herceptin on the same cell 
lines, the compact antibody was found to be a stronger inhibitor of cell viability. 
The specificity of the anti-proliferative activity of Erb-hcAb for target cells was 
assessed by testing the effects on ErbB2-negative A431cells. In this case, no 
inhibition of cell viability was obtained, as also found for Herceptin (Fig. 39). 
Taken together, these data indicated that the compact antibody is able to 
discriminate between antigen-positive and antigen-negative cells, and to specifically 
inhibit growth and survival of target cells. 
 
 
 
 
Figure 39. Effects of Erb-hcAb on tumour cell growth. 
Dose-response curves of ErbB2-positive, SKBR3 cells 
(black symbols), or ErbB2-negative A431 cells (empty 
symbols), treated for 72 h with Erb-hcAb (circles), or 
with Herceptin (rhomboids). 
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 A3. THE PREDICTION OF ERBICIN STRUCTURE  
This part of my research project was carried out in the laboratories of Prof. Anna 
Tramontano of the University of Rome “La Sapienza”, where I performed 
computational analyses to build a structural model of the scFv Erbicin, using 
homology modelling techniques. 
 
 
KEY ASPECTS IN MOLECULAR MODELLING 
 
Protein structure prediction has attracted significant attention in the last few decades 
since the knowledge of the three dimensional structure of a protein is instrumental to 
get information on its function, its relationships and interactions with other proteins in 
the organism (81-83). Particularly, molecular modelling of immunoglobulins appears 
to be of great interest, since it may be able to predict the conformation of the antigen 
binding site of an antibody. 
The experimental observation that in many cases a protein sequence is able to direct 
its folding (84), implies that a code must exist that correlates the sequence 
information to the corresponding three-dimensional structure. 
In principle, the free energy corresponding to every possible protein conformation 
could be calculated, and its native fold could be identified as the structure associated 
to the minimum free energy. Nevertheless, the incorrect evaluation of the free energy 
of a protein could represent a serious limit  to this approach. 
The number of known protein sequence is at least one order of magnitude higher 
than the number of known protein structures, and the gap between the two 
collections is continuously increasing, since the rapidity at which protein sequences 
are produced is still enormous compared with the speed at which protein structures 
are determined, despite the many advances in techniques for protein structure 
determination. 
The possibility of predicting the protein structure from its sequence would allow to 
explain the sequence-structure-function relationship; to this purpose, a number of 
new methods have been developed and evaluated. Among the methods for protein 
structure prediction, homology modelling seems to be the most promising (85), 
especially when the identity between the two sequences that are compared is high, 
as it is the case for the immunoglobulins. 
 
 
Homology modelling: basic techniques 
The basic concept of homology modelling relies on the observation that if a protein of 
unknown structure (target) shares a significant sequence identity with a protein of 
known structure, the two protein will have a similar structure, so that the latter can be 
used as a “template” to build a model of the target (86).  
The quality of a model depends essentially on the percentage of residue identity or 
similarity of the template and target sequences.  
It has been calculated that, for proteins with sequence identity ≥ 50%, the root mean 
square deviation (rmsd) of the backbone atoms of the core region, i.e. the average 
distance between the atoms of superimposed proteins, is ≤ 1.0 Å, meaning that 
proteins are largely superimposable. 
On the other hand, in case of sequence identity ≤ 20% the rmsd  is > 1.8 Å, meaning 
that significant structural differences occur (87). 
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 Immunoglobulin structure 
Immunoglobulins are multidomain proteins whose basic domain, consisting of about 
100 amino acids, is formed by two beta-sheets packed face to face and linked by a 
disulphide bridge (88) (Fig. 40). 
 
 
 
  Figure 40: Immunoglobulin domain. 
 
 
 
The variable domains of the light and heavy chains (VL and VH, respectively) 
represents the immunoglobulin elements responsible for antigen binding. VL and VH 
domains contain hypervariable regions involved in the antigen binding site, which is 
formed by six hypervariable loops, named complementarity-determining regions 
(CDR). The three CDRs of the light chain are named L1, L2 and L3 in order of 
appearance in the sequence, whereas the three CDRs of the heavy chain are 
indicated as H1, H2 and H3 (Fig.41).  
The core of the double beta-sheet structure, named framework, shows a similar 
conformation in different variable domains, as the internal residues are highly 
conserved. Residues that form the interface between VL and VH domains are also 
highly conserved. For this reason, the prediction of an immunoglobulin structure 
mainly consists in the prediction of its hypervariable loops. 
 
 
         
 
Figure 41: The complementarity 
determining regions (CDR) of a 
single chain antibody fragment 
(scFv). The three 
complementarity determining 
regions of VL  and VH domains 
are represented.
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The prediction of the structure of  immunoglobulin loops 
Loops are regions of the polypeptide chain that have a low degree of regularity and 
where insertions and deletions frequently occur during evolution (89). In some cases, 
loops have been found to be the nucleation site for protein folding and very often they 
are involved in the catalytic mechanism of enzymes or in interaction surfaces 
between different proteins (e. g. the antigen recognition site of antibodies). 
A widely used technique to predict loop conformation was proposed by Jones and 
Thirup (90). The basic idea consists in the search in the database of solved protein 
structures for two regions closely matching the segments preceding and following the 
loop to be modelled (“stems”). These segments should be separated by the same 
number of residues as those forming the loop. The assumption is that the structure of 
the loop is correlated to the structure of its “stem” regions.  
Tramontano and Lesk (91) simulated a model building experiment with the 
immunoglobulin loops. The basic steps consisted of: 
I. Searching the database for loops similar in conformation to those selected for 
the experiment to verify if the loop is indeed predictable by using a knowledge-
based approach; 
II. Searching the database for regions matching the stems of each loop, separated 
by the appropriate number of residues; 
III. Comparing the loops selected in step II with those selected in step I. 
 
Canonical structures of the immunoglobulin loops 
In 1987 Cyrus Chothia and Arthur M. Lesk, analysing the atomic structures of an 
antigen-binding fragment (Fab) and VL fragments of immunoglobulins, identified the 
few residues that, on the basis of their packing, hydrogen bonding or ability to 
assume unusual ϕ, ψ or ω conformations, are primarily responsible for the main-
chain conformation of the hypervariable regions (92).  
Five of the six CDR loops (loops L1, L2, L3, H1, H2), in spite of their high sequence 
variability, can assume a small number of main chain conformations, called canonical 
structures. These are determined by the length of the loop and the presence of a few 
key residues in the loop and/or in the framework. Therefore, the main chain 
conformation of the loops can be successfully predicted from the antibody sequence, 
leading to successful predictions of structures.  
The third CDR of VH chains (H3) is much more variable in length, sequence and 
structure than the other antigen-binding loops. The lack of a method to predict the 
structure of H3, which is located at the center of the antigen-binding site, and 
therefore plays a central role in the antigen recognition process, usually impairs the 
prediction of the complete immunoglobulin binding site (93). 
 
BUILDING A MODEL FOR ERBICIN scFv  
 
The general outline of a comparative modelling experiment follows this procedure: 
A. Identifying which protein, if any, can be used as a template 
B. Alignment of the sequence of the target protein to that of the template 
C. Building the backbone of the target in the aligned regions by using the 
coordinates of the backbone of the corresponding positions of the template 
D. Building the backbone of the regions where insertion and deletions have 
occurred 
E. Positioning the side-chains in the model 
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 F. Refining of the stereochemistry; 
G. Evaluating the accuracy of the final model. 
 
• Kabat numbering 
A preliminary step in scFv Erbicin model construction was the definition of Kabat (94) 
numbering code for the scFv, a widely adopted standard for numbering the residues 
of an antibody, based on sequence variability during evolution (95).  
The alignment with Kabat database was performed as indicated in 
http://www.bioinf.org.uk/cgi-bin/AndrewMartin/abseq.perl (96). On the basis of 
Chothia and Lesk definition of the canonical structures of immunoglobulin loops, we 
identified all the residues forming the six hypervariable loops of Erbicin: 
 
 
                           Light chain                                              Heavy chain 
 
L1 loop 
L26 S    
L27 S 
L27A G 
L27B S 
L27C V 
L27D S 
L27E T 
L27F S 
L28 Y 
L29 Y 
L30 P 
L31 Q 
L32 L 
L33 V 
H2 loop 
H52 Y 
H52A P 
H53 G 
H54 D 
H55 S 
H56 D 
 
H3 loop
H94 R 
H95 W 
H96 R 
H97 D 
H98 S 
H101 P 
 
H1 loop
H26 G 
H27 Y 
H28 S 
H29 F 
H30 T 
H31 S 
H32 Y 
 
L2 loop L3 loop
L91 Y 
L92 M 
L93 G 
L94 S 
L95 G 
L95A Q 
L96 Y 
L50 S 
L51 T 
L52 N 
 
 
 
 
 
 
 
 
 
 
 
 
 
• Database search  
The most commonly used programs for database searches are FASTA, BLAST and 
SSEARCH.  
FASTA searches for similarities between one sequence (the query) and a database 
of sequences. It performs the search in two steps: first the program finds the 
sequence having the largest number of short perfect matches for each comparison, 
which are subsequently scored and joined. In the second step, the sequences with 
the highest scores are aligned to the query sequence for display. 
BLAST (Basic Local Alignment Search Tool) compares each database sequence 
with the query in a separate protein-protein pairwise comparison where the program 
finds regions of similarity between the query and the database sequences. The 
output consists of gapless alignments of any parts of two sequences. 
SSEARCH performs a full pairwise alignment between the query sequence and each 
of the sequences in the database. 
Protein BLAST program was used to search in the PDB database (Protein Data 
Bank, database of solved protein structures) for the protein template used for the 
scFv Erbicin model building at http://www.ncbi.nlm.nih.gov/blast/Blast.cgi.  
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 The sensitivity of a method in finding a sequence match is related both to the 
algorithm used and to the scoring matrices that assign a specific penalty to each 
residue mutation in the alignment. Many available scoring matrices are available, 
usually based on the tabulation of amino acid replacement observed in homologous 
sets of aligned sequences or, more recently, of structurally aligned three-dimensional 
structures. 
Essentially, two sets of amino acid substitution matrices are used by FASTA, BLAST 
and SSEARCH: the BLOSUM and the PAM series. Each series includes several 
matrices, corresponding to different expected evolutionary distances between the 
query and the target sequences. For Erbicin alignment, BLOSUM62 matrix was used. 
 
• Sequence alignment 
The alignment provided by a database search is usually not optimal and often 
includes only regions of high similarity between the query sequence and the 
database hits, so that it is necessary to realign the selected template to the target 
sequence.  
The “correct” sequence alignment is the alignment in which structurally equivalent 
positions are correctly aligned. More importantly, it is possible to carefully analyse the 
alignment by verifying that insertions or deletions are not interrupting regular 
elements of secondary structure in the template, or occurring in the core of its 
structure.  
Pairwise sequence alignment programs consider all possible alignments and gap 
positions and create the alignment with the highest score and the fewest gaps. In 
general, they use the alignment method of Needleman and Wunsch (97). The 
program also evaluates the significance of the alignment using a statistical method: 
one of the two sequences is repeatedly shuffled, maintaining its length and 
composition, and then realigned to the other sequence. The quality score of the 
actual alignment can be compared with the average quality score of the shuffled 
alignments. Most of the errors in homology modelling derive directly from an incorrect 
alignment. On the basis of these theoretical rules, the alignments between query VH 
and VL with the database VH and VL sequences were checked. 
A murine scFv, identified as 1A6U in PDB, showed the best alignment with both 
Erbicin VH and VL sequences, and was chosen as the template for Erbicin model 
building. The alignment between Erbicin (VH and VL sequences) and 1A6U is shown 
below, where the six hypervariable loops are depicted in red: 
 
• VL            
>PDB|1A6U|1A6U-L b1-8fragment: fv fragment; 
          Length = 108 
 
 Score = 265 (98.3 bits), Expect = 3.1e-24, P = 3.1e-24 
 Identities = 59/111 (53%), Positives = 75/111 (67%) Gaps = 3/111 (2%) 
 
Query:    2 AVVLREPSFSVSPWRDQSHSTCGLSSGSVSTSYYPQLVPARPQARLHATLIYSTNTRSSG 61 
            AVV +E + + SP    +  TC  S+G+V+TS Y   V  +P   L   LI  TN R+ G 
Sbjct:    1 AVVTQESALTTSPGETVT-LTCRSSTGAVTTSNYANWVQEKPD-HLFTGLIGGTNNRAPG 58 
 
Query:    62 VPDRFSGSILGNKAALTITGAQADDESDYYCVLYMGSGQYVFGGGTKLTVL 112 
             VP RFSGS++GNKAALTITGAQ +DE+ Y+C L+  S  +VFGGGTKLTVL 
Sbjct:    59 VPARFSGSLIGNKAALTITGAQTEDEAIYFCALWY-SNHWVFGGGTKLTVL 108 
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• VH             
 
>PDB|1A6U|1A6U-H b1-8fragment: fv fragment; 
          Length = 120 
 
 Score = 331 (121.6 bits), Expect = 3.1e-31, P = 3.1e-31 
 Identities = 63/114 (55%), Positives = 81/114 (71%) no gaps 
 
Query:    1 QVQLLQSAAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRY 60 
            QVQL Q  AE+ KPG S+K+SCK SGY+FTSYW+ WV+Q PG+GLEW+G I P    T+Y 
Sbjct:    1 QVQLQQPGAELVKPGASVKLSCKASGYTFTSYWMHWVKQRPGRGLEWIGRIDPNSGGTKY 60 
 
Query:    61 SPSFQGQVTISADKSISTAYLQWSSLKASDTAVYYCARWR---DS--PLWGQGT 109 
             +  F+ + T++ DK  STAY+Q SSL + D+AVYYCAR+     S    WGQGT 
Sbjct:    61 NEKFKSKATLTVDKPSSTAYMQLSSLTSEDSAVYYCARYDYYGSSYFDYWGQGT 114 
 
 
 
VL alignment 
ScFv Erbicin VL is constituted by lambda light chains. Sequence identity with 1A6U 
scFv was found to be 53%, so that the probability of a casual alignment is very low 
(10-24). All key residues of the hypervariable loops are conserved, although two gaps 
(insertions) in the framework region (L20 and L39) were found.  
 
VH alignment 
Sequence identity with 1A6U was found to be 55%, so that the probability of a casual 
alignment is very low (10-31). All key residues of the hypervariable loops are 
conserved.  
 
Template scFv: 1A6U fragment 
It is a Fv fragment isolated from Mus musculus, solved by X-ray diffraction at 2.10 Å 
resolution (98), whose structure is shown in Fig 42. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 42. 1A6U fragment from Mus 
musculus, identified as 1A6U in 
PDB database. 
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 The final alignment obtained for Erbicin and 1A6U sequences contain both aligned 
regions and insertions. The coordinates of the backbone of the template in the 
aligned regions are used to build the corresponding regions of Erbicin scFv. 
Insight II (99) was used to visualise 1A6U and to build Erbicin scFv model. Our first 
task was to analyse the crystallographic cell of the 1A6U template, to evaluate all 
possible contacts occurring in the cell. No contacts were found in the hypervariable 
regions inside the crystallographic cell. 
Then, backbone template residues were substituted with the corresponding residues 
of Erbicin, to obtain a first, incomplete, representation of the Erbicin scFv structure 
(Fig. 43). This preliminary model lacks the coordinates of regions containing gaps. 
Erbicin VL chain showed 3 gaps compared to the template sequence: two insertions 
in the framework and one in L3 loop; on the other hand, Erbicin VH chain showed 
only one gap compared to its template sequence, corresponding to a deletion in H3 
loop, which is a very common condition, due to the high sequence variability of the 
third hypervariable heavy chain loop. 
 
 
   
 
Figure 43. Representation of the backbone (on the left), and of the 
secondary structures (on the right) of the scFv Erbicin, modelled on 1A6U 
template.  
 
 
 
 
Gaps. Insertions and deletions are usually located in exposed regions of the protein, 
such as loops. The prediction of these fragments is the most difficult part of the 
modelling procedure since they do not correspond to any template region and 
because they are much less regular and much more variable than the elements of a 
regular secondary structure. 
There is no general method to solve the “gap problem”. In Erbicin model building the 
gap problem was solved by a database search on known protein structures for 
regions with a conformation similar to that of the regions adjacent to the target loop, 
i.e. the “stems”, and separated by the same number of residues as those of the loop.  
 
Side-chains. Once a partial model for the backbone is obtained, side-chains are 
added to it. Conserved aminoacids tend to maintain the same side-chain 
conformation, and Insight II program works in the same way (Fig. 44). 
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Figure 44. Side chains of the scFv Erbicin model. 
  
 
Furthermore, side-chains must be added to the backbone avoiding clashes and 
unfavourable interactions, defined as “bumps”. Since each aminoacid side chain 
preferentially assumes a limited number of conformations (100), these can be used in 
combination with some energy-based method, to avoid unfavourable interactions. 
 
Energy minimisation.  After a complete model has been built, it has to be evaluated 
and optimised through the use of specific programs. Unfavourable steric interactions 
must be relieved and the stereochemistry should be optimised by a few cycles of 
energy minimisation. 
Energy minimisation algorithms will only find the local minimum close to the starting 
conformation so that this step will not improve the model, but it makes the structure 
since stereochemically more reasonable. 
 
Structural characteristics of Erbicin model 
 
The antigen binding site of Erbicin was investigated in details.  
We found a prevalence of hydrophobic aromatic residues either in the hypervariable 
loops and in the framework regions that precede and follow the complementarity-
determining regions (CDR).  
The antigen-binding site has a concave shape due to the small size of the H3 loop. 
We hypothesised the formation of a hydrophobic pocket, in which the antigen could 
be accommodated. 
Trp H333 and Arg H359 are unusually exposed on the surface, which suggests that 
they are involved in antigen-recognition. 
Erbicin antigen-binding site is also rich in framework residues; most of them are 
hydrophobic, such as Tyr L51, Phe L100, Trp H347, and Ile H350.  
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 On the other hand, there are some CDR residues of L1 and H1 loops positioned at 
the edge of these hypervariable loops, that seem to not interact with the antigen, as 
they are quite distant from the antigen-binding site. 
This hypothesis is confirmed by the analysis of several antibody structures, in which 
the edge of  L1 and H1 loops are not involved in antigen recognition (101) (Fig. 45).  
 
 
 
 
 
                                                                  
Figure 45. Model of the scFv 
Erbicin.  
a) “Ribbon” representation. The six 
hypervariable loops are coloured in 
purple (L1), orange (L2), fuchsia 
(L3), light blue (H1), yellow (H2) and 
white (H3). b) 90° rotated structure 
with respect to a). c) Solvent 
accessible surface of Erbicin. 
Residues are coloured on the basis 
of their hydrophobicity. The 
orientation is as in b). 
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 PART B. A NEW DIAGNOSTIC STRATEGY FOR 
RHEUMATOID ARTHRITIS 
The second phase of my research activity was carried out in the Immunopathology 
laboratory of the “Umberto I” hospital, Nocera Inf. (SA), under the supervision of Dr. 
Paola Sabatini. 
The object of the research was the definition of an effective diagnostic strategy for 
early diagnosis of rheumatoid arthritis.  
 
ANALYSES OF SERUM SAMPLES  
 
A prospective study was performed on 350 unselected serum samples from patients 
chosen on the basis of their clinical features. The sera, collected from January 2005 
to May 2007, derived from outpatients attending clinics at the hospital “Umberto I” of 
Nocera Inferiore, were consecutively recruited for the study. Serum levels of two RA 
markers (RF and anti-CCP antibodies) were measured in the collected samples, 
using different diagnostic methodologies. Four groups of patients were analysed: 
 
1. 100 patients affected by rheumatoid arthritis, (mean age 52, range 29-75 
years) diagnosed according to the revised American College of 
Rheumatologists (ACR) criteria. Sixty of these patients (60%) were classified 
as early arthritis patients, as the disease duration was of less than one year.  
 
2. 100 patients affected by chronic hepatitis C, recruited from the outpatients 
attending at the Infectious Diseases clinic. These patients show elevated 
levels of RF, due to tissue inflammation caused by the hepatitis C virus and 
due to the intensive therapies administered to them to fight the infection.  
 
3. 53 patients affected by other connective tissue diseases, recruited from the 
Immunopathology laboratory outpatients (11 Systemic Lupus Erythematosus, 
12 Mixed Connective Tissue Disease, 13 Sjögren Syndrome, 5 Progressive 
Systemic Sclerosis, 9 CREST Syndrome, 1 Bechet Disease). RF was often 
detected in this group of patients, in some cases at high levels.  
 
4. 97 Healthy subjects (sex- and age matched), recruited from healthy blood 
donors from the Transfusion centre. Normally, RF may be detected only in 
about 1-2% of healthy people.  
 
Table 3 summarises the sample groups: 
 
Groups of patients Number 
Rheumatoid arthritis patients (RA) 100 
Chronic hepatitis C virus patients (HCV) 100 
Connective tissue disease patients (C) 53 
Healthy subjects (H) 97 
Table 3.  
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 All samples were tested to detect IgM-RF using: 
• The nephelometric assay 
• The multiplexed cytofluorimetric assay 
• ELISA assays for anti-CCP antibodies.  
 
All the assays were performed in duplicate. 
 
 
RHEUMATOID FACTOR DETECTION 
 
1. Nephelometric assay 
 
A commercial automated agglutination test was performed to detect the rheumatoid 
factor (RF) in the serum of selected patients. The assay was carried out by using 
polystyrene particles coated with an immuno-complex, consisting of human γ-
globulin/anti-human γ-globulins from sheep (Fig. 46). 
 
 Figure 46. Schematically 
representation of a polystyrene 
bead, coated with an immuno-
complex consisting of human 
IgG/anti-human IgG from sheep. 
Rheumatoid factor binds the Fc 
fragment of the coated human 
IgG.         
 
Polystyrene 
particle
Human
IgG
Sheep IgG
anti-human
IgG Human
RF
 
          
 
 
Diluted serum samples were mixed to the coated particles and the turbidity of the 
suspension was measured by a nephelometer, an instrument that measures the 
amount of light reflected by the suspended particles. This instrument includes a light 
beam (source beam) and a light detector, positioned at one side of the source beam 
(usually 90°). Particle density is a function of the light reflected into the detector from 
the particles.  
A more popular term for this instrument is turbidimeter. A nephelometric turbidimeter 
is able to monitor light reflected off the particles, instead of the attenuation due to 
cloudiness.  
Analytes concentration was determined by using a standard curve, obtained using 
reference standards at known concentrations. Serum samples having >15 U/mL were 
considered positive.  
The results, shown in the Fig. 47, indicated that: 
 
• 77% of RA patients were highly positive for IgM-RF 
 
• 68% of HCV patients showed high positive values for IgM-RF 
 
• 64% of Connective disease patients were positive for IgM-RF 
 
• 27% of healthy people showed positive values of IgM-RF 
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Figure 47. Rheumatoid factor values detected by the 
nephelometric assay. RA: Rheumatoid arthritis patients, HCV: 
Hepatitis C Virus patients, C: Connectivitis patients, H: Healthy 
people 
 
2. FIDISTM Rheuma Multiplex assay 
 
FIDIS Rheuma is a semi-automated test, based on a flow-cytometric measurement of 
analytes, for RF detection. An immunoassay was performed using a set of 
microspheres able to bind the rheumatoid factor in the serum samples. 
A specific positive control, named calibrator, was used in each assay to determine 
the cut-off value of the test. 
The microsphere reagent was mixed with either the calibrator, or with the diluted 
controls and samples in a filter membrane microtiter plate. After 30 min of incubation 
at room temperature, microspheres were washed by filtration using a manometric 
pump. Next, an anti-human IgM phycoerythrin-conjugated was added to each 
microwell, and plates were incubated for 30 min at room temperature.  
The flow-cytometer detected the amount of IgM-RF bound to the target antigens, 
coated on microspheres, in 10-20 sec. During this period, the system first 
categorised each microsphere set, according to its orange or red fluorescent colour, 
and then it determines the average green fluorescence from PE conjugate, providing 
a quantitative determination of each autoantibody specificity. 
The reports can be automatically generated by the FIDIS database management 
software. Results were expressed in international units per mL (IU/mL) according to 
the first British Standard for Rheumatoid Arthritis. All samples showing values higher 
than 30 IU/mL were considered positive. 
The results of these assays, shown in Fig. 48, indicated that 
             
• 80% of RA patients were highly positive for IgM-RF 
 
• 56% of HCV patients showed high positive values for IgM-RF 
 
• 51% of Connective disease patients were positive for IgM-RF 
 
• Only 13% of healthy people showed positive values of IgM-RF 
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Figure 48. Rheumatoid factor values detected by FIDIS Rheuma 
assay. Groups are as in Fig. 18. 
 
 
ANTI-CCP ANTIBODY ASSAY 
 
ELISA assays were performed to detect anti-CCP autoantibodies in serum samples, 
using a synthetic cyclic citrullinated peptide as the antigen.  
In each assay, a positive control sample, named calibrator, was used to determine 
the cut-off value of the test. 
Serum samples were firstly diluted at 1:101 and then distributed in microwells with 
the coated antigens. Each sample was tested twice, to ensure data reproducibility.  
After 30 min, microwells were extensively washed with PBS solution, to remove the 
unbound sample. Then, a secondary antibody, an anti-human IgG HRP-conjugated, 
was added to each well; plates were then incubated for 30 min at room temperature.  
After an extensive wash with PBS solution, 100µL of TMB Chromogen were added to 
each well and plates were incubated in a dark place at room temperature.  
Finally, to each well was added a dilute sulphuric acid solution to stop the HRP 
enzymatic reaction. The absorbance (OD) of each well at 450 nm was determined by 
a spectrophotometer within one hour from the reaction stop.  
Anti-CCP antibodies were determined by using a 5 point standard curve, obtained 
from five standard samples, supplied by the manufacturer.  
The samples analysed were classified as negative, weakly positive, moderately 
positive or strongly positive, as described in the Methods section.  
The results of these assays, shown in Fig. 49, indicated that 
 
• 100% of RA patients were positive for anti-CCP antibodies 
 
• 0% of HCV patients showed a positive values of anti-CCP antibodies 
 
• 2% of Connective disease patients were positive for anti-CCP antibodies 
 
• 0% of healthy people showed positive values of anti-CCP antibodies 
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Figure 49. Anti-CCP antibodies detected by ELISA assay 
 
 
As reported in the Figure, the anti-CCP test had an elevated specificity and sensitivity 
for RA diagnosis, since this marker was detectable only in RA patients. All but one 
patient of the other groups were negative for anti-CCP antibodies. The only non-RA 
patient showing a positive value of anti-CCP antibodies was affected by Bechet 
disease, a rare autoimmune disorder causing small blood vessels inflammation, 
known as vasculitis. However, this sample showed a moderately positive value (42 
U/ml) of anti-CCP antibodies. 
These results indicated the great diagnostic potential of this test.  
  
 
 
COMPARISON OF NEPHELOMETRY versus FIDIS RHEUMA TEST 
 
The results obtained by measuring RF in selected patients, using two different 
methods, nephelometry and multiplex cytofluorimetric assay, were compared.  
Two parameter were chosen to compare the results obtained by testing selected 
patients with the nephelometric and the cytofluorimetric assays: sensitivity and 
specificity. 
Sensitivity is defined as the probability that, given the presence of disease, an 
abnormal test result indicates the presence of disease. Specificity is defined as the 
probability that, given the absence of disease, a normal test result excludes the 
disease. The data of this comparative analysis are shown in Fig. 50. 
The multiplex cytofluorimetric assay (FIDIS Rheuma) appeared to be more sensitive 
than the nephelometric test, as it was able to identify as positive 3% of patients 
affected by rheumatoid disease, but defined as negative by the nephelometric 
method. 
Furthermore, FIDIS Rheuma test was found to be more specific than the 
nephelometric method, as it detected a lower number of RF positive samples in the 
HCV, C and H groups, compared to conventional tests.  
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 The results indicated that FIDIS Rheuma has a higher sensitivity (80%) and 
specificity (87%) than nephelometry (77% and 73%, respectively). Results were 
obtained by comparing RA and H groups only. 
 
77%
80%
68%
56%
64%
51%
27%
13%
0%
20%
40%
60%
80%
100%
Po
si
tiv
e 
sa
m
pl
es
 (%
)
RA HCV C H
Groups
NEPHELOMETRY vs FIDIS RHEUMA TEST
NEPHELOMETRY
FIDIS RHEUMA
 
Figure 50. Comparison between RF values detected by 
nephelometric and by FIDIS Rheuma assays. 
 
 
 
COMPARISON OF NEPHELOMETRY versus FIDIS RHEUMA TEST 
COUPLED TO ANTI-CCP TEST 
 
The results reported above indicated a better performance of the cytofluorimetric 
FIDIS assay with respect to the conventional nephelometric test. 
We then planned a novel combinatorial approach to set up an optimal test, exhibiting 
the highest sensitivity and specificity for RA detection. 
As mentioned in the Introduction, a very promising test for RA is based on the use of 
anti-cyclic citrullinated peptides antibodies, which were found to be specific markers 
of inflammation in rheumatoid arthritis disease. 
Thus, we evaluated the diagnostic efficacy and the potential improvement in RA 
diagnosis of the FIDIS Rheuma test combined to the anti-CCP tests, in comparison 
to the conventional nephelometric test. The results are shown in Fig. 51. 
When the FIDIS Rheuma test was used in combination to the anti-CCP test, a 
significant increase of sensitivity was detected with respect to the results obtained 
with the nephelometric assays (100% versus 77%, respectively, in RA group). 
Moreover, by comparing the percentage of positive samples detected in RA group 
using the combined test (100%, Fig. 51) to the percentage obtained using the FIDIS 
Rheuma test (80%, Fig. 51), we confirmed the effectiveness of the combined test. 
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Figure 51. Comparison between nephelometry and FIDIS Rheuma 
test coupled to the anti-CCP antibodies assay. 
 
 
 
 
STATISTICAL ANALYSES  
  
Statistical analyses were performed to evaluate the reliability of data and to verify if 
the differences found between results obtained using the FIDIS Rheuma test, 
nephelometric test and anti-CCP test were statistically significant. 
McNemar's test was used to calculate the p-value, and we accepted a p-value ≤0.05 
as being statistically significant.  
Due to the small differences observed between the two methods, the Yate’s 
correction factor was necessarily applied to the McNemar's test. 
By comparing the two RF detection methods, a significant value of the result 
differences occurring between the FIDIS Rheuma test and the nephelometric test 
was observed in HCV (p = 0.02) and in H group (p = 0.002), whereas the differences 
occurring between the results obtained in RA (p = 0.37) and C groups (p = 0.07) 
were not significant (p > 0.05).  
The results were shown in Fig. 52. 
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p = 0.37*
p = 0.02 p = 0.07*
p = 0.002* 
Figure 53. Statistical significance of the results obtained using the two RF 
detection tests: nephelometric and FIDIS Rheuma assays. In blue statistically 
significant values, in black statistically not significant value are reported. * = 
Yate’s correction factor applied 
 
 
 
 
Statistical significance was evaluated also comparing results obtained using 
nephelometric test with those obtained using the combination formed by FIDIS 
Rheuma test coupled to the anti-CCP assay.  
A significant p-value (p <0.05) was obtained in RA, HCV and H groups but not in C 
groups. This was probably due to the small number of samples of the C group.  
The effectiveness of the combined tests was confirmed by statistical analyses, 
indicating that, when FIDIS Rheuma test was used in combination with the anti-CCP 
test, a statistically significant improvement occur to the test specificity for the 
diagnosis of rheumatoid arthritis.  
Hence, we may conclude that a combined approach that utilises the highest specific 
and sensitive diagnostic assays (FIDIS Rheuma RF coupled to the anti-CCP test) is 
the most efficient tool for early RA diagnosis. 
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DISCUSSION 
 
 
A NEW TOOL FOR ANTICANCER THERAPY: THE ANTI-ErbB2 COMPACT 
ANTIBODY 
 
Conventional anti-cancer therapies, being characterised by the absence of 
specificity, may produce debilitating side effects, and sometimes may be ineffective. 
Immunotherapy represents a valuable alternative strategy to fight cancer, since it 
uses molecules of the immune system, mainly antibodies, specifically directed to 
selected cancer cells. Sometimes referred to as biological therapies, these new 
treatments have renewed interest and research activity in immunology. This is based 
on the evidence that antibodies can be specifically directed to target cancer cells, 
where they may induce direct cytotoxic effects, e.g. Fc-mediated cellular cytotoxicity, 
and they can also target cytotoxic molecules into cells. 
The current strategy in cancer immunotherapy research is based on the 
characterisation of new tumour-associated antigens (TAA), i.e. proteins expressed at 
high levels mostly on tumour cell surface. 
A good candidate as a tumour-associated antigen is the ErbB2 receptor, highly 
expressed in tumour cells of different origin, such as breast, ovary and lung 
carcinomas. The accessibility of ErbB2 on cell surface and its implications in the 
development of malignancy of these tumours make it an attractive target for 
immunotherapy.  
Several groups of researchers have produced different types of antibodies directed to 
ErbB2. A humanised version of an anti-ErbB2 antibody (Herceptin) was produced in 
2000 and it is currently in use for the treatment of advanced breast cancer (27).  
Although the great potential of whole antibody molecules in the treatment of cancer, 
some limitations occurred in the use of engineered antibodies as therapeutic agents, 
such as the development of immune responses against humanised mAb and the low 
efficacy of antibody effector functions due to the large size of immunoglobulins (155 
kDa), that makes difficult their penetration in solid tumours. To avoid these 
disadvantages, single-chain variable fragments (scFv) have been produced. These 
chimeric molecules retain the specificity of the original immunoglobulin, despite the 
removal of the constant regions. They are useful tools as immunotherapeutic agents, 
as they can easily penetrate solid tumours. 
Actually, fully human scFvs may be isolated using the phage-display technology, a 
method based on the construction of large repertoires of human antibody variable 
regions expressed on filamentous phages, and fused to a phage coat protein. 
Recently, in the laboratories of Proffs. Giuseppe D’Alessio, Renata Piccoli and 
Claudia De Lorenzo, a novel human anti-ErbB2 scFv has been isolated from a large 
phage-display library, through a double selection strategy, performed on live cells. 
This scFv, named Erbicin, showed interesting properties for immunotherapy. Erbicin 
was found to bind specifically to ErbB2-positive cells, to inhibit the receptor 
autophosphorylation and to be internalised in target cells where strongly inhibits their 
proliferation.  
However, the monovalent nature of the scFv as well as its supposed rapid clearance 
from the bloodstream, could limit its use as a therapeutic agent selective for 
mammary carcinoma cells. 
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 To overcome these limitations, the aim of my research activity was to transform 
Erbicin scFv in a more stable molecule, by fusing Erbicin to a human Fc domain.  
The engineered antibody was defined “compact Ab”, i.e. an antibody molecule with 
the following features: 
• molecular size of about 100 kDa, higher than a scFv molecule, but smaller 
than a whole antibody 
• two binding-sites 
• potential prolonged clearance from the bloodstream 
• effector functions mediated by the Fc domain: ADCC, antibody-dependent 
cellular cytotoxicity and CDC, complement-dependent cytotoxicity. 
 
To generate the compact antibody anti-ErbB2, the cDNA encoding the scFv Erbicin 
was cloned into the Signal pIgPlus plasmid, downstream to a human IgG1 Fc 
domain. The recombinant vector was then amplified in E.coli JM101 bacterial cells, 
and trasfected in CHO eukaryotic cells.  
Single clones, expressing the recombinant protein, were identified by electrophoresis 
analyses and ELISA assays, using anti-human Fc antibodies. A protein species, with 
the expected molecular weight of the chimeric protein and immuno-positive to anti-Fc 
antibodies, was identified. 
Large-scale experiments were then performed to produce the compact antibody in 
suitable amount to test its biological activity. The immunoagent was purified from the 
culture medium by a one-step purification procedure, using an immuno-affinity 
chromatography on a protein A-agarose column, and then analysed by SDS-PAGE 
and Western blotting. The compact antibody, isolated as a pure protein, was named 
Erb-hcAb. 
 
Analyses were then carried out to extensively characterise the compact Ab.  
Erb-hcAb features are summarised below:  
• The compact antibody is expressed as a disulphide-linked dimer 
• Erb-hcAb binds selectively and with high affinity to ErbB2 over-expressing 
cells 
• The apparent binding affinity of the compact antibody for the ErbB2 receptor 
was found to be 1 nM, a value that confirms the high binding affinity of the 
compact Ab for its natural antigen 
• When compared to Herceptin, a commonly used anticancer drug, Erb-hcAb 
was found to be able to recognise with higher affinity its antigen 
When Erb-hcAb was tested on cell cultures, to analyse its effects on cell viability, it 
was found to be able to induce a strong and selective anti-proliferative action on 
target, i.e. ErbB2 expressing, cells. Erb-hcAb was found to be even more effective 
than Herceptin. 
No effects were instead detected when the compact Ab was tested on ErbB2-
negative cell lines. 
On the basis of these results, we might conclude that Erb-hcAb has a high 
therapeutic potential, as it fully satisfies the conditions required for an effective 
anticancer agent:  
I. it is a fully human immunoagent, thus low, if any, immunogenicity is expected to 
be elicited; 
II. it recognises one of the most specific tumour-associated antigens (ErbB2) with 
high affinity; 
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 III. it is effective in inhibiting tumour cell growth. This effect is selective for ErbB2-
positive cells. 
Moreover, I performed computational analyses aimed at building a model of Erbicin 
structure, which represents the antigen binding moiety of the compact Ab, using the 
homology modelling technique. This was relevant to define the topology of the 
antigen binding site, as well as to design strategies aimed at improving the 
immunoagent affinity for the ErbB2 receptor. 
These studies, carried out in the laboratories of Prof. Anna Tramontano, University of 
Rome, “La Sapienza”, provided an accurate model of the three dimensional structure 
of the scFv Erbicin. 
Taken together, these data suggest that Erb-hcAb is a promising new anticancer 
agent, and supports the concept that, following humanised monoclonal and scFvs, a 
third generation of immunoagents, the human compact antibodies, may represent the 
format of choice for the therapy of solid tumour.  
The new compact Ab was recently patented (Patent PCT/EP02/07671 on “Human 
mini-antibody cytotoxic for tumour cells which express the ErbB2 receptor” 
G.D’Alessio, R.Piccoli, C. De Lorenzo, D.B. Palmer, M.A. Ritter, owned by Biotechnol 
S.A., Oeiras, Portugal). 
 
 
 
A NEW STRATEGY FOR EARLY DIAGNOSIS OF RHEUMATOID ARTHRITIS. 
 
Rheumatoid Arthritis (RA) is an autoimmune disease that causes chronic 
inflammation of the joints. Autoimmune diseases are illnesses that occur when the 
body tissues are mistakenly attacked by its own immune system. Auto-antibodies are 
then produced, targeted to their own body tissues where they induce inflammation.  
Rheumatoid arthritis is referred to as a systemic illness, since it can affect multiple 
organs of the body. It affects approximately 0.5% of the world population. 
Although the cause of RA is still unknown, most rheumatologists agree that the 
earlier RA patients are treated, the better is their prognosis. This implies that an early 
diagnosis is crucial for therapy establishment and patient health. 
In 1987 the American College of Rheumatology (ACR) has defined in details the 
criteria for the diagnosis of rheumatoid arthritis. These criteria include the presence in 
the patient serum of the rheumatoid factor.  
Rheumatoid factor (RF) is a group of auto-antibodies reacting with various antigenic 
sites located on the Fc fragment of the IgG class immunoglobulins.  
The RF test is considered the basic screen and hallmark for RA, since approximately 
80% of RA patients have positive RF values. Moreover, higher RF levels are also 
seen in more severe forms of the disease and this condition is a severe prognostic 
factor for patients.  
Actually, the amount of rheumatoid factor in blood is usually measured by the 
nephelometric test. Nephelometry is based on the principle that a dilute suspension 
of small particles will scatter light (usually a laser) passed through it. The amount of 
scattered light is determined by collecting the light at an angle of about 70 or 75 
degrees. 
Recently, a new immunoassay for the simultaneous detection of IgM RF directed 
against human and animal IgG, the FIDIS Rheuma test, was set up. It is based on 
flow cytometric measurements of RF serum levels, using a set of 100 fluorescent 
uniform-size (5.5 µm) polystyrene microspheres, coated with the specific antigen.  
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 Moreover, in recent years an emerging group of auto-antibodies has been described 
in RA, which may have a role in the development of rheumatoid arthritis: the anti-
citrullinated peptides antibodies (ACPA).  
Citrullination, or peptidylarginine deimination, is a post-translational modification 
catalysed by a specific enzyme, peptidyl-arginine deaminase (PAD), in which the 
guanidine moiety of arginine is hydrolysed, and replaced by an oxygen atom.  
Due to the central role of these antibodies in RA, a biochemical test was developed 
to detect anti-citrulline antibodies in sera of RA patients: the anti-cyclic citrullinated 
peptides (anti-CCP) ELISA test. 
The aim of my research work was: (i) to evaluate the effectiveness of the FIDIS 
Rheuma test in comparison to the commercial nephelometric test for IgM-RF 
detection; (ii) to test the possibility  to use anti-cyclic citrullinated peptide (anti-CCP) 
antibodies as early markers for rheumatoid arthritis.  
To do this, 350 unselected serum samples were tested by a prospective study to 
detect both RF, using multiplex and nephelometric methodologies, and anti-CCP 
antibodies. Four categories of patients were analysed: 100 patients affected by RA; 
100 patients affected by hepatitis C virus chronic infection (HCV); 53 patients 
affected by other connective tissue disease  (C); 97 healthy blood donors (H). 
Results indicated that the multiplex cytofluorimetric assay (FIDIS Rheuma) is more 
sensitive than the nephelometric test, as it was able to identify as positive 3% of 
patients affected by RA, but defined as negative by the nephelometric test. 
Furthermore, FIDIS Rheuma test resulted more specific than the nephelometric 
method, as it detects a lower number of RF positive samples in the HCV, C and H 
groups, compared to the conventional nephelometric test. Moreover, FIDIS Rheuma 
test shown higher sensitivity (80%) and specificity (87%) than nephelometry (77% 
and 73%, respectively).  
Furthermore, we demonstrated that anti-CCP test has elevated specificity and 
sensitivity for RA diagnosis, since this marker was detectable only in RA patients. 
This indicated that anti-CCP test is a very promising test for RA and a specific marker 
of inflammation. On the basis of these results, a novel combined approach was 
planned, to set up an optimal test, with the highest sensitivity and specificity for RA 
diagnosis. 
To this purpose, the FIDIS Rheuma test was combined to the anti-CCP test in order 
to improve their efficacy in RA diagnosis.  
The results indicated that, by combining the FIDIS Rheuma test to the anti-CCP test, 
a significant increase of sensitivity was detected with respect to the results obtained 
with the nephelometric assay (100% sensitivity versus 77%).  
Statistical analyses, performed using the McNemar's test, confirmed that a 
statistically significant (p-value <0.05) improvement to the test specificity for the 
diagnosis of rheumatoid arthritis occur when FIDIS Rheuma test was used in 
combination with the anti-CCP test.  
We conclude that the combined test (FIDIS Rheuma test coupled to anti-CCP test) is 
a successful approach to obtain the highest diagnostic specificity and sensitivity and 
to generate a useful tool for early RA diagnosis. 
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A human, compact, fully functional anti-ErbB2 antibody as a novel
antitumour agent
C De Lorenzo1, A Tedesco1, G Terrazzano2, R Cozzolino1, P Laccetti1, R Piccoli1 and G D’Alessio*,1
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A new human, compact antibody was engineered by fusion of a human, antitumour ErbB2-directed scFv with a human IgG1 Fc
domain. Overexpression of the ErbB2 receptor is related to tumour aggressiveness and poor prognosis. This new immunoagent
meets all criteria for a potential anticancer drug: it is human, hence poorly or not immunogenic; it binds selectively and with high
affinity to target cells, on which it exerts an effective and selective antiproliferative action, including both antibody-dependent and
complement-dependent cytotoxicity; it effectively inhibits tumour growth in vivo. Its compact molecular size should provide for an
efficient tissue penetration, yet suitable to a prolonged serum half-life.
British Journal of Cancer (2004) 91, 1200–1204. doi:10.1038/sj.bjc.6602110 www.bjcancer.com
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Immunotherapy represents an effective strategy to fight cancer,
mainly based on antibodies specifically directed to selected cancer
cells (Trikha et al, 2002; Ross et al, 2003). Obstacles to full success
of present-day immunotherapy include: (i) immune responses
against non-human, or even humanised antibodies (Kuus-Reichel
et al, 1994); (ii) the large size of antibodies, which hinders their
diffusion into bulky tumours. Fully human, small-sized anti-
tumour immunoagents would overcome these risks, and provide
safe, highly selective and effective antitumour drugs.
A good candidate as a tumour-associated antigen, and an
attractive target for immunotherapy, is ErbB2 (also known as Her-
2/Neu), a transmembrane tyrosine kinase receptor, overexpressed
in breast carcinomas, for which it is a marker of poor prognosis
(Slamon et al, 1987). We recently isolated a novel human anti-
ErbB2 single-chain variable fragment (scFv) from a large phage-
display library (Griffin 1) through a double selection strategy
performed on live cells (De Lorenzo et al, 2002). This scFv, named
Erbicin, specifically binds to ErbB2-positive cells, inhibits the
receptor autophosphorylation, is internalised in target cells and
strongly inhibits their proliferation (De Lorenzo et al, 2002).
However, the small size of the scFv and its expected rapid
clearance from the bloodstream, as well as its monovalent nature,
could limit its use as a therapeutic agent selective for mammary
carcinoma cells.
A significant addition to the anticancer arsenal would be the
construction of a new anti-ErbB2 immunoagent from a human, per
se cytotoxic scFv and a human Fc domain. This fully human
antitumour antibody would be a compact, reduced version of an
IgG, with the antiproliferative effect of the scFv moiety on tumour
target cells, combined with the ability of the Fc moiety to induce
both antibody-dependent cellular cytotoxicity (ADCC) and com-
plement-dependent cytotoxicity (CDC). Yet, such a compact
antibody is expected to have (Demignot et al, 1990; Yokota et al,
1993; Powers et al, 2001) a more protracted half-life and higher
tumour retention than the parental scFv, but improved penetration
properties in solid tumours with respect to full-size IgG agents.
MATERIALS AND METHODS
Cell cultures and antibodies
The SKBR3 cell line from human breast cancer, the A431 cell line
from human epidermoid carcinoma, and Chinese hamster ovary
(CHO) cells (all from American Type Culture Collection, Rockville,
MD, USA) were cultured in RPMI 1640 (Gibco BRL, Life
Technologies, Paisley, UK). The TUBO cell line from a BALB-neu
T mouse-derived mammary lobular carcinoma (kindly provided
by Dr G Forni, University of Turin, Italy) was grown in DMEM
(Gibco BRL). The media were supplemented with 10% foetal
bovine serum (20% for TUBO cells), 50 U ml1 penicillin, and
50mg ml1 streptomycin (all from Gibco BRL).
The antibodies used were: Herceptin (Genentech, South San
Francisco, CA, USA); monoclonal anti-human IgG1 (Fc specific,
Sigma, St Louis, MO, USA); horseradish peroxidase-conjugated
goat anti-mouse immunoglobulins (Pierce, Rockford, IL, USA);
horseradish peroxidase-conjugated goat anti-human affinity-iso-
lated IgG (Fc specific) (Sigma).
Peripheral blood lymphocytes
Peripheral blood lymphocytes (PBL) were obtained from periph-
eral blood mononuclear cells (PBMC) isolated by centrifugation on
Lymphoprep gradients (Axis Shield PoC AS, Oslo, Norway) from
normal donor buffy coats obtained from the Blood Bank of the
Medical School of the University of Naples ‘Federico II’. After the
separation, PBL were washed twice and incubated in RPMI 1640
medium (Gibco BRL) for 2 h at 371C to remove adherent cells. The
Received 11 May 2004; revised 1 July 2004; accepted 2 July 2004;
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nonadherent cells were used as natural cytotoxic effectors without
any additional treatment.
Construction and production of the anti-ErbB2 Erb-hcAb
In a previous paper (De Lorenzo et al, 2002), we reported the
isolation of a novel human anti-ErbB2 scFv, selected by panning
the Griffin 1 phage library on live cells with a subtractive selection
strategy based on two combinations of ErbB2-positive and
-negative cell lines. The cDNA coding for the anti-ErbB2 scFv was
amplified from vector pHEN2 by PCR using as forward and reverse
primers oligonucleotides containing at their 50 end a HindIII site
and a BamHI site, respectively: (50-CCCCCCAAGCTTCAGGTG
CAGCTGTTG-30; 50-AACCGCGGATCCGCACCTAGGACGGTCAG-
30). The PCR fragment was then digested with HindIII and BamHI
(New England Biolabs, Hertfordshire, UK) for cloning into the
corresponding sites in plasmid pIg1plus (R & D Systems,
Minneapolis, USA), downstream to the leader sequence and
upstream to the hinge-CH2-CH3 sequence, respectively, of a
human IgG1 heavy chain constant region (Fc).
The fusion protein was produced by transfecting CHO cells with
the recombinant vector. In brief, cells grown in RPMI containing
10% FCS at 70–80% confluency were transfected with 5 mg of
expression vector using the Superfect reagent (Qiagen, Valencia,
CA, USA). Stable transfectants were selected in the presence of
G418 (Sigma) at a concentration of 1 mg ml1. Expression of the
antibody construct was determined in the culture medium by
quantitative ELISA. For recombinant protein production, trans-
fected CHO cells were expanded to near confluence in selective
medium containing neomycin, and then were grown for 3– 4 days
in serum-free medium.
The recombinant fusion protein, henceforth termed Erb-hcAb,
secreted by transfected CHO cells, was purified from culture
medium by affinity chromatography on a protein A-Ceramic
Hyper DsF column (BioSepra, Cergy-Saint-Christophe, France)
loaded with 300– 500 ml of conditioned medium, washed with 10
volumes of 100 mM Tris-HCl, pH 8.0 containing 0.5 M NaCl, and 10
volumes of 10 mM Tris-HCl, pH 8.0. The protein eluate was
obtained with 50 mM glycine pH 3.0, and immediately neutralised
with 1/10 volume of 1 M Tris-HCl, pH 8.0.
ELISA assays
ErbB2-positive SKBR3 cells and ErbB2-negative A431 control cells,
harvested in nonenzymatic dissociation solution (Sigma), were
washed and transferred to U-bottom microtitre plates (1 105 cells
per well). After blocking with PBS containing 6% bovine serum
albumin (BSA), cells were incubated with conditioned medium or
purified immunoagents in ELISA buffer (PBS/BSA 3%) for 90 min.
The pelleted cells were washed, resuspended in 100 ml of ELISA
buffer, and incubated with an anti-human IgG (Fc-specific) mAb
(Sigma) or anti-myc mAb 9E10 (Evan et al, 1985), for detection of
Erb-hcAb and Erbicin (containing the myc tag), respectively. Goat
anti-mouse HRP-conjugated immunoglobulins (Pierce, Rockford,
IL, USA) were used for detection of bound antibodies. After 1 h,
the plates were centrifuged, washed with ELISA buffer, and reacted
with 3,30,5,50-tetramethylbenzidine (TMB) (Sigma). Binding values
were determined from the absorbance at 450 nm, and reported as
the mean of at least three determinations (s.d. p5%).
Cell growth inhibition assays
Cells were seeded in 96-well, flat-bottom plates; SKBR3 and TUBO
cells at a density of 1.5 104 well; A431 at a density of 5 103 well.
After addition of the protein under test viable cells by the Trypan
blue-exclusion test were counted at suitable time intervals. Cell
survival was expressed as percent of viable cells in the presence of
the protein under test with respect to control cultures grown in the
absence of the protein. Typically, cell survival values were obtained
from at least three separate experiments in which triplicate counts
were determined; standard deviations were below 5%.
ADCC and CDC tests
Target and control cells were detached from culture dishes with a
cell dissociation solution (Sigma) and transferred to round-bottom
96-well plates (2 104 cells per well). For ADCC assays, target or
control cells were treated with the immunoagents (3 mg ml1 of
serum-free medium) and peripheral blood lymphocytes (PBL) at
371C for 3 –4 h. For CDC assays, cells were incubated at 371C with
human serum. Cultures were performed in triplicate in a final
volume of 200 ml. Controls included target cells incubated in the
absence of effector, or in the presence of either serum or
immunoagent alone. Tumour cell lysis was determined by
measuring the release of lactate dehydrogenase (LDH) using a
LDH detection kit (Roche, Mannheim, Germany). ADCC or CDC
were calculated as the percent of cytolysis measured in the
presence of immunoagent and PBL or human serum, for ADCC
and CDC, respectively, taking as 100% the maximal LDH release
determined by lysis of target cells with 1% Triton X-100.
In vivo antitumour activity
All experiments were performed with 6-week-old female Balb/
cAnNCrlBR mice (Charles River Laboratories, Calco, Italy). TUBO
cells (5 105) were suspended in 0.2 ml sterile PBS and injected
subcutaneously (day 0) in the right paw. At day 7, when tumour
started to appear, the mice were divided into two groups. At day
15, when tumours were clearly detectable, Erb-hcAb dissolved in
PBS was administered at a site remote from that of tumour
implantation, at doses of 2.5 mg kg1 of body weight for 7 times at
72 h intervals. The second group of control animals was treated
with identical volumes of sterile PBS. During the period of
treatment, tumour volumes (V) were measured with caliper and
calculated by the formula of rotational ellipsoid V¼AB2/2 (A is
the axial diameter, B the rotational diameter). All mice were
maintained at the animal facility of the Department of Cellular and
Molecular Biology and Pathology, University of Naples Federico II.
Animal studies were conducted in accordance with the Italian
regulation for experimentation on animals. All in vivo experiments
were carried out with ethical committee approval and met the
standards required by the UKCCCR guidelines (Workman et al,
1998).
RESULTS
Construction and characterisation of a human anti-ErbB2
compact antibody
We generated a new anti-ErbB2 immunoagent by fusing the scFv
Erbicin with a human IgG1 Fc domain. The IgG-like protein has a
reduced molecular weight, and contains all functionally relevant
antibody regions. The cDNA coding for the human anti-ErbB2
scFv was amplified by PCR and cloned into a eukaryotic
expression vector containing the human IgG1 Fc sequence. The
recombinant plasmid, sequenced to confirm faithful cloning, was
stably transfected in Chinese hamster ovary cells, and expressed as
a secretion product into the culture medium. After purification by
affinity chromatography, the final yield of the fusion protein was
1.5 mg l1. The immunoagent was named Erb-hcAb (anti-ErbB2
human compact antibody). When Erb-hcAb was analysed by SDS–
PAGE (Figure 1), it was found to migrate under reducing
conditions with the expected molecular size of about 50 kDa, and
as a dimer of about 100 kDa under nonreducing conditions. This
indicated that the fusion protein is expressed as a disulphide-
linked dimer. Western blotting analysis performed with an
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anti-human Fc mAb demonstrated immunoreactivity of the
purified, dimeric protein with 100 kDa size (Figure 1).
When the ability of the recombinant fusion protein to bind
ErbB2-positive cells was analysed by ELISA assays (Figure 2A),
Erb-hcAb was found to fully retain the specificity of the original
scFv for mammary carcinoma SKBR3 ErbB2-overexpressing cells.
It did not react instead with ErbB2-negative cells such as A431 cells
(from human epidermoid carcinoma), which overexpress the
ErbB1 EGF receptor from the same ErbB family. The apparent
binding affinity of the compact antibody for the ErbB2 receptor,
that is, the concentration corresponding to half-maximal satura-
tion, was about 1 nM, comparable to the values of 4 and 5 nM,
determined for the parental scFv, and Herceptin, a humanised
anti-ErbB2 monoclonal, respectively (see Figure 2A). Presumably,
the four-fold increased avidity with respect to Erbicin is due to the
acquired bivalency of Erb-hcAb for ErbB2.
Biological effects of Erb-hcAb on ErbB2-positive tumour
cells
The effect of Erb-hcAb on tumour cell growth was assessed by
measuring the survival of SKBR3 cells treated with increasing
concentrations of Erb-hcAb. As shown in Figure 2B, the anti-ErbB2
Erb-hcAb inhibited the growth of SKBR3 cells in a dose-dependent
fashion, with an antiproliferative effect more pronounced than that
observed for Herceptin, and no effects on the proliferation of
ErbB2-negative A431 cells (see Figure 2B).
To investigate whether Erb-hcAb was capable of recruiting
immune effector functions in vitro, assays for cytolysis of tumour
cells as induced by PBL, or complement, were performed. To
determine the capacity of Erb-hcAb to trigger ADCC towards
antigen-expressing cells, ErbB2-positive and ErbB2-negative con-
trol cells were incubated for 3 h with increasing amounts of effector
PBL in the absence or in the presence of Erb-hcAb (3 mg ml1). As
shown in Figure 3A, Erb-hcAb effectively lysed SKBR3 target cells
in the presence of PBL. The extent of lysis reached almost 100% of
treated cells, whereas Herceptin, used as a positive control,
induced about 60% lysis. The basal level of cytotoxicity was
measured in the presence of PBL (see Figure 3A) or Erb-hcAb
alone (data not shown). No effects were detected in parallel assays
carried out with ErbB2-negative cells, such as A431 (data not
shown), or when Erb-hcAb was replaced by the parental anti-
ErbB2 scFv, lacking the Fc domain (see Figure 3A). These results
indicate the specificity of the Erb-hcAb-dependent cell-mediated
cytolytic activity, clearly based on both binding abilities of the
immunoagent: (i) to the cognate receptor with its antigen binding
sites; (ii) to natural killer cells with its Fc effector domain.
To test the ability of Erb-hcAb to induce CDC against ErbB2-
positive tumour cells, SKBR3 target cells were incubated for 2 or
6 h with Erb-hcAb (at 3 or 10mg ml1 concentrations) in the
absence or the presence of human serum as a source of
complement. As illustrated in Figure 3B, Erb-hcAb was found to
effectively lyse SKBR3 cells in the presence of serum, with an
average specific lysis of 50% after 2 h, increased to about 70% after
additional 4 h of incubation with 10 mg ml1 of Erb-hcAb (see
Figure 3B). Heat inactivation of serum completely abolished the
complement-dependent lysis. Moreover, CDC was not detected
when ErbB2-negative A431 cells were incubated with Erb-hcAb
and human serum (data not shown). Similarly, as expected
(Drebrin et al, 1988), no lysis was detectable when SKBR3 cells
were treated with Herceptin in the presence of human serum (see
Figure 3B).
In vivo antitumour activity of Erb-hcAb
For in vivo studies, Erb-hcAb was tested on murine TUBO tumour
cells expressing ErbB2 of rat origin (Rovero et al, 2000). In vitro,
TUBO cells were found to be sensitive to the treatment with Erb-
hcAb with an IC50 of 0.5 mM. This indicated cross-reactivity
between the human immunoagent and rat ErbB2 (Rovero et al,
1 3 4
100 kDa
50 kDa
2
Figure 1 SDS–PAGE of purified Erb-hcAb. Erb-hcAb was run under
reducing (lane 2) and nonreducing (lane 3) conditions. Lane 4: Western
blot analysis of the sample run in lane 3 tested with an anti-human IgG1 (Fc
specific) antibody. Molecular weight standards are in lane 1.
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Figure 2 Effects of Erb-hcAb on ErbB2-positive (SKBR3) and ErbB2-
negative (A431) cells. (A) ELISA assays of SKBR3 cells (black symbols) and
A431 cells (empty symbols) tested with Erb-hcAb (circles), the parental
anti-ErbB2 scFv (rhomboids), or Herceptin (squares). (B) Dose–response
curves for ErbB2-positive SKBR3 cells (black symbols), or ErbB2-negative
A431 cells (empty symbols), treated for 72 h with Erb-hcAb (circles), or
Herceptin (squares).
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2000). This may not be surprising, as the structures of the two
homologs are highly superimposable (Cho et al, 2003).
When administered to mice, TUBO cells induce tumours very
similar to the alveolar-type human lobular mammary carcinomas
(Di Carlo et al, 1999). As shown in Figure 4, the treatment of mice
bearing TUBO tumours with seven doses, at 72 h intervals, of
2.5 mg kg1 of Erb-hcAb induced a dramatic reduction (96%) in
tumour volume. During the period of treatment, the animals did
not show signs of wasting or other visible signs of toxicity.
DISCUSSION
The results described in this report show that the Erb-hcAb
immunoagent has a high therapeutic potential, as it fully satisfies
the conditions required for a successful anticancer agent: it is a
fully human immunoagent, hence presumably with a reduced or
no immunogenicity; it recognises with high affinity one of the most
specific tumour-associated antigens, such as ErbB2; it displays
effective antibody effector functions; it is effective in inhibiting
target cell growth both in vitro and in vivo. Furthermore, its size
should be better suited to therapeutic applications than either a
small scFv, or full-size IgG-like molecules.
Previous reports have shown the feasibility of cloning single-
gene constructs encoding fusion proteins made up of murine scFv
and Fc fragments (Shu et al, 1993; Li et al, 2000; Xu et al, 2000).
Recently, a recombinant, human scFv-Fc antibody has been
reported (Powers et al, 2001) to mediate in vitro ADCC and
endure a much longer serum half-life in vivo when compared to its
parental scFv. However, the protein was produced in yeast with
yeast-controlled glycosylation; furthermore, it was found to be
heterogeneous, obtained in very low yields, and only partially
glycosylated. It should be noted that Erb-hcAb, as reported above,
was prepared instead in CHO cells, a mammalian model certainly
closer than yeast to human cells.
Herceptin, currently used for treatment of advanced breast
cancer (Baselga et al, 1999; Stebbing et al, 2000), is a humanised
version of a murine anti-ErbB2 antibody. Its antitumour activity is
mostly based on its ability to downregulate ErbB2 and induce
ADCC (Sliwkowski et al, 1999), but, as previously reported
(Drebrin et al, 1988), it does not elicit CDC. The new immunoagent
Erb-hcAb instead displays a strong CDC effect, and has a reduced
molecular size (100 kDa) with respect to that of Herceptin
(155 kDa). It has been shown (Demignot et al, 1990; Yokota et al,
1993; Powers et al, 2001) that in an immunoagent of about 100 kDa
the advantage of the prolonged half-life of an intact antibody is
composed with an increased extravascular diffusion, both very
expedient features for targeting solid tumours.
Taken together, the data reported here suggest that Erb-hcAb is
a promising new anticancer agent, and supports the concept that,
after humanised monoclonals and scFvs, a third generation of
immunoagents, human compact antibodies, may represent the
format of choice for the therapy of solid tumours.
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Figure 4 In vivo suppression of tumour growth by Erb-hcAb. Tumour
growth was followed in mice inoculated s.c. with 5 105 TUBO mammary
carcinoma cells. Control animals (black circles) were treated with sterile
PBS solution. Treated animals (white circles) were injected with Erb-hcAb,
starting at day 15. Seven doses, each of 2.5 mg kg1 of body weight, were
administered at 72 h intervals.
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Figure 3 Antibody-dependent and complement-dependent cytotoxicity
assays of Erb-hcAb. (A) SKBR3 cells treated with PBL as effector cells at
four different ratios: in the absence (white bars), or in the presence of Erb-
hcAb (black bars). Erbicin, the parental anti-ErbB2 scFv (striped bars), and
Herceptin (grey bars) were used as a negative and a positive control,
respectively. (B) ErbB2-overexpressing SKBR3 cells were incubated for 2
or 6 h, in the presence of human serum as a source of complement, with
Erb-hcAb at a concentration of 3 mg ml1 (shaded bars) or 10 mg ml1
(black bars). Herceptin (10 mg ml1) was used as a negative control (white
bars).
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